BPS[LOCATION_003] Protocol Number:2521
Protocol Version Number:3.0, Date: Jun 22, [ADDRESS_169893] Crossover, Fully Replicate, 
Bioequivalence Study of Generic TacrolimusCapsules andPrograf¬ÆCapsulesin 
Healthy Volunteers under Fasting Conditions
BPS[LOCATION_003] Protocol Number: 2521
Protocol Version Number: 3.0
Protocol Version Date: Jun 22,2021
Sponsor: U.S. Food and Drug Administration
PROTOCOL APPROVAL SIGNATORY PAGE
I am aware of, and agree to comply with, all of the procedures contained within this 
protocol and requirements of applicable regulatory agencies:
_____________________________________
Sanjida Mahjabeen, Ph.D. Date (Mmm dd, yyyy)

 BPS[LOCATION_003] Protocol Number : 2521  
Protocol Version Number:  3.0, Date: Jun 22, 2021 
Tacrolimus Capsule  
Fasting C onditions  
 
Page 3 of 68 
REVISION HISTORY 
Version # 
(Version 
Date)  Affected Sections  
1.0 (Aug 07 , 
2020) N/A 
2.0 (Dec 23, 
2020)  As per discussion between sponsor and BPSI/BPS[LOCATION_003], t he 
following sections were revised from the previously approved 
protocol:  
i) Protocol Title Pages and Headers  ‚Äì Protocol Version and 
Date revised to Version 2.0 and Dec 23, 2020, 
respectively.  
ii) Updated BPS[LOCATION_003] telephone and fax number. Following 
sections have been updated:  
‚Ä¢ Title page  
‚Ä¢ Section SPONSOR, INVESTIGATORS AND 
FACILITIES 
‚Ä¢ Section INVESTIGATOR CREDENTIALS  
iii) Section Table of Contents ‚Äì updated pagination  
iv) Tuberculosis (TB) Test and/or Questionnaire have been 
removed from the study . Following sections have been 
updated:  
‚Ä¢ Section 2.0  TABLE OF STUDY PROCEDURES  
‚Ä¢ Section 5.1.1 Screening (Visit 1)  
‚Ä¢ Section 7.3  Exclusion Criteria  
‚Ä¢ Section 8.[ADDRESS_169894] (has been deleted)  
‚Ä¢ APPENDIX A ‚Äì SCHEDULE OF EVENTS  
v) Included light smokers to this study and removed cotinine 
test. Following sections have been updated:  
‚Ä¢ Section 1.0 SYNOPSIS  
‚Ä¢ Section 2.0 TABLE OF STUDY PROC EDURES  
‚Ä¢ Section 4.1 Study Objective  
‚Ä¢ Section 5.0 STUDY DESIGN  
‚Ä¢ Section 6.0 STUDY POPULATION  
‚Ä¢ Section 7.[ADDRESS_169895] SELECTION AND 
WITHDRAWAL/TERMINATION  
‚Ä¢ APPENDIX A ‚Äì SCHEDULE OF EVENTS  
 BPS[LOCATION_003] Protocol Number : 2521  
Protocol Version Number:  3.0, Date: Jun 22, 2021 
Tacrolimus Capsule  
Fasting C onditions  
 
Page 4 of 68 
‚Ä¢ APPENDIX B ‚Äì CLINICAL LABORATORY 
ASSESSMENT  
vi) The test for SARS -CoV- [ADDRESS_169896] 
been updated:  
‚Ä¢ Section 1.0 SYNOPSIS  
‚Ä¢ Section 2.0 TABLE OF STUDY PROCEDURES  
‚Ä¢ Section 8.5.[ADDRESS_169897]  
‚Ä¢ APPENDIX A ‚Äì SCHEDULE OF EVENTS  
vii) Section SPONSOR, INVESTIGATORS AND 
FACILITIES has been updated for the IRB official name.  
viii) Section 7.3 Exclusion Criteria has been updated regarding 
Systolic blood pressure and temperature normal range, 
timeframe for the restriction of be verages containing 
grapefruit and/or pomelo consumption. 
ix) Section 7.5 Study Restrictions has been updated regarding 
timeframe for the restriction of beverages containing 
grapefruit and/or pomelo consumption. 
x) Section 8.5.4 Pulse Oximetry and Respi[INVESTIGATOR_148234]. 
xi) Section 8.6 Vital Signs has been updated regarding vital 
sign normal ranges.  
xii) End-of-Study (EOS) now has one -week ¬±[ADDRESS_169898] been updated:  
‚Ä¢ Section 2.0 TABLE OF STUDY PROCEDURES  
‚Ä¢ Section 5.1.[ADDRESS_169899] -Study [End- of-Study (EOS)]/Early 
Termination  
xiii) Section 8.5.[ADDRESS_169900] thermometer.      
xiv) Section 9.3 Drug Inventory has been updated regarding  
the purchase of stu dy drug. 
xv) Section 11.1.1 Treatment -emergent adverse events 
(TEAEs)  added sentence ‚ÄúThe PI/sub- I will be 
responsible for determining whether a TEAE is 
possibly related to the SARS- CoV -2 and document 
accordingly. ‚Äù 
 BPS[LOCATION_003] Protocol Number : 2521  
Protocol Version Number:  3.0, Date: Jun 22, 2021 
Tacrolimus Capsule  
Fasting C onditions  
 
Page 5 of 68 
xvi) Section 11.[ADDRESS_169901] .  
xvii) In Section 13.[ADDRESS_169902] 
been updated to: ‚ÄúIn a case whe re SARS -CoV- 2 related 
TEAEs lead to the withdrawal or dismissal  of 
approximately 5 % or more of the dosed subjects, a 
subgroup analysis related to Adverse Events (AE) may 
be performed . And the safety listings and tables for AE 
with subgroup and the total s afety population will 
both be presented .‚Äù 
xviii)  Section 13.2.2 Statistical Analysis of Pharmacokinetic 
Data, updat ed statistical model regarding dosing in 
groups.  
xix) In Section 15.3 Study Completion/Termination , related 
sentences have been updated to ‚ÄúBioPharma Ser vices 
[LOCATION_003] Inc. and/or the Sponsor reserve the right to terminate 
the study at any time , and  for any reason related to the 
safety of subjects or due to any other non -study 
specific reason .‚Äù 
xx) Minor administrative/grammatical revisions were also 
made.  
The study ICF was also revised to reflect applicable changes.  
3.0 (Jun 2 2, 
2021)  As per discussion between sponsor and BPSI/BPS[LOCATION_003], the 
following sections were revised from the previously approved 
protocol:  
i) Protocol Title Pages and Headers  ‚Äì Protocol Version and 
Date revised to Version 3.0 and Jun 22, 2021,  
respectively.  
ii) Non or light smoking has been removed from Section 1.0. 
4.1, [IP_ADDRESS] and 6.0.  
iii) Confinement has been  updated to read as: ‚Äú From at least 
[ADDRESS_169903] dose, 
for a total of approximately 84 hours for each study 
period.‚Äù And Footer in Section 2.0 and 5.2 has been  
revised accordingly . 
iv) Additional measurements  of the heart rate and blood 
pressure have been added at [ADDRESS_169904] -dose for 
 BPS[LOCATION_003] Protocol Number : 2521  
Protocol Version Number:  3.0, Date: Jun 22, 2021 
Tacrolimus Capsule  
Fasting C onditions  
 
Page 6 of 68 
additional safe ty monitoring. Therefore , Sections 1 .0, 2.0, 
8.6 and Appendix A ha ve been  updated. 
 
v) Section 7.1 sample size has been updated for the 
clarification.  
vi) MedWatch has been  replaced with ‚Äú FDA Adverse Event 
Reporting System (FAERS)‚Äù in Section 11.3  
vii) Section 12.1.1 and 13.1 has been updated to further clarify 
the samples to be assayed and  data to be included in the 
pharmacokinetic analysis . 
viii) AUC [ADDRESS_169905] been updated.  
ix) Section 13.3.[ADDRESS_169906].  
x) Section 13.3.3 has been  updated to include the following 
statements in line with the SAP:  Descriptive statistics of 
all quantitative measurements from all clinical laboratory 
parameters will be presented by [CONTACT_148257], laboratory parameter, and visit . 
 BPS[LOCATION_003] Protocol Number : 2521  
Protocol Version Number:  3.0, Date: Jun 22, 2021 
Tacrolimus Capsule  
Fasting C onditions  
 
Page 7 of 68 
TABLE OF CONTENTS  
TITLE PAGE .................................................................................................................... 1 
REVISION HISTORY ..................................................................................................... 3 
TABLE OF CONTENTS  ................................................................................................. 7 
SPONSOR, INVESTI GATORS AND FACILITIES  .................................................. 10 
INVESTIGATOR CREDENTIALS  ............................................................................. 11 
1.0 SYNOPSIS  ............................................................................................................. 12 
2.0 TABLE OF STUDY PROCEDURES  .................................................................. 15 
3.0 INTRODUCTION: BACKGROUND INFORMATION AND SCIENTIFIC 
RATIONALE  ......................................................................................................... [ADDRESS_169907] Information  ............................................................................................. 18 
4.0 STUDY OBJECTIVE  ........................................................................................... 21 
4.1 Study Objective  ....................................................................................................... 21 
5.0 STUDY DESIGN ................................................................................................... 21 
5.1 Discussion of Study Design  .................................................................................... 21 
5.1.1  Screening (Visit 1)  .................................................................................................. 22 
5.1.2  Treatment Phase (Visit 2 to 14)  ............................................................................... [ADDRESS_169908]-Study [End- of-Study (EOS)]/Early Termination  ............................................ [ADDRESS_169909] SELECTION AND WITHDRAWAL/TERMINATION  ................ 25 
7.1 Sample Size  ............................................................................................................. 25 
7.2 Inclusion Criteria  ..................................................................................................... 26 
7.3 Exclusion Criteria  .................................................................................................... 27 
7.4 Inform ed Consent Procedure  ................................................................................... 31 
7.5 Study Restrictions  ................................................................................................... 31 
7.6 Withdrawal and Dismissal  ...................................................................................... 34 
8.0 STUDY PROCEDURES  ....................................................................................... 35 
8.1 Demographics and Other Baseline Characteristics  ................................................. 35 
8.1.1  Demographics  .......................................................................................................... 35 
8.1.2  Medical History  ....................................................................................................... 35 
8.1.3  Medication History  .................................................................................................. 35 
8.1.4  Clinical Laboratory Assessments  ............................................................................ 36 
8.2 Food and Fluid Intake  ............................................................................................. 36 
8.3 Dosing ..................................................................................................................... 36 
 BPS[LOCATION_003] Protocol Number : 2521  
Protocol Version Number:  3.0, Date: Jun 22, [ADDRESS_169910]  ................................................................................................... 37 
8.6 Vital Signs  ............................................................................................................... 38 
8.7 ECG  ......................................................................................................................... 38 
8.8 Health Monitoring  ................................................................................................... 38 
8.9 Sample C ollection and Processing  .......................................................................... 38 
8.10  Sample Shipment  ..................................................................................................... 39 
9.0 DRUG PRODUCTS  .............................................................................................. 40 
9.1 Drug Information  ..................................................................................................... 40 
9.2 Labeling, Maintenance, and Retention .................................................................... 40 
9.3 Drug Inventory ........................................................................................................ 40 
9.4 Disposition of Unused Tacrolimus  .......................................................................... 41 
10.0  POTENTIAL RISKS AND BENEFITS  .............................................................. 41 
10.1.1  Potential Risks  ........................................................................................................ 41 
10.1.2  Potential Benefits  ................................................................................................... 41 
11.0  SAFETY ASSESSMENT  ...................................................................................... 42 
11.1  Definitions  ............................................................................................................... 42 
11.1.1  Treatment -emergent adverse events (TEAEs) ........................................................ 43 
11.2  Characteristics of an Adverse Event  ....................................................................... 44 
11.2.1  Relationship to Study Drug .................................................................................... 44 
11.2.2  Expectedness of SAE  ............................................................................................. 44 
11.2.3  Severity Assessment  ............................................................................................... 45 
11.3  Adverse Events and Serious Adverse Events Reporting  ......................................... 45 
11.4  Procedures for Reporting Pregnancy  ....................................................................... 47 
12.0  BIOANALYTICAL ANALYSIS  ......................................................................... 48 
12.1  Analytical Procedures  ............................................................................................. 48 
12.1.1  Samples to be Assayed  ........................................................................................... 48 
12.1.2  Analyte(s) in Biological Matrix  ............................................................................. 48 
12.1.3  Incurred sample reproducibility  ............................................................................. 48 
13.0  PHARMACOKINETIC AND STATISTICAL ANALYSIS  ............................. 49 
13.1  Pharmacokinetic and Statistical Analysis Data Set  ................................................. 49 
13.2  Analysis of Pharmacokinetic Data  .......................................................................... 49 
13.2.1  Pharmacokinetic Analysis  ...................................................................................... 50 
13.2.2  Statistical Analysis of Pharmacokinetic Data  ........................................................ 51 
 BPS[LOCATION_003] Protocol Number : 2521  
Protocol Version Number:  3.0, Date: Jun 22, 2021 
Tacrolimus Capsule  
Fasting C onditions  
 
Page 9 of 68 
13.3  Safety Analysis  ........................................................................................................ 55 
13.3.1  Safet y Data Set  ....................................................................................................... 55 
13.3.2  Safety Listings  ........................................................................................................ 55 
13.3.3  Safety Tables .......................................................................................................... 55 
13.4  Bioequi valence Criteria [7, 10]  ............................................................................... 56 
14.0  ETHICAL CONSIDERATIONS / PROTECTION OF HUMAN SUBJECTS [ADDRESS_169911]  ...................................................................................... 57 
14.3  Informed Consent Form  .......................................................................................... 57 
14.4  Confidentiality  ......................................................................................................... 57 
14.5  Compensation for Participation  ............................................................................... 58 
15.0  ADMINISTRATIVE CONSIDERATIONS  ....................................................... 60 
15.1  Revisions and/or Amendments to the Protocol  ....................................................... 60 
15.2  Investigator Responsibilities  ................................................................................... 60 
15.3  Study Completion/Termination  ............................................................................... 60 
15.4  Sponsor Visits  ......................................................................................................... 61 
16.0  DATA MANAGEMENT/RECORD KEEPI[INVESTIGATOR_1645]  ................................................ 61 
16.1  Source Data  ............................................................................................................. 61 
16.2  Quality of Data  ........................................................................................................ 61 
16.3  Retenti on of Documents  .......................................................................................... 61 
17.0  REFERENCES  ...................................................................................................... 62 
APPENDIX A ‚Äì SCHEDULE OF EVENTS  ................................................................ 63 
APPENDIX B ‚Äì CLINICAL LABORATORY ASSESSMENT  ................................. 65 
APPENDIX C ‚Äì LIST OF COMMON ABBREVIATIONS  ....................................... 66 
APPENDIX D ‚Äì PROGRAF¬Æ LABEL  .......................................................................... 68 
 
 BPS[LOCATION_003] Protocol Number : 2521  
Protocol Version Number:  3.0, Date: Jun 22, 2021 
Tacrolimus Capsule  
Fasting C onditions  
 
Page 10 of 68 
SPONSOR, INVESTIGATORS AND FACILITIES  
Principal 
Investigator:  [INVESTIGATOR_124]. Artan Markollari , M.D.  
BioPharma Services [LOCATION_003] 
Inc. 
 
 Pharmacokinetic  / 
Statistical Facility:   
 
  
 
 
 
 
Clinical 
Laboratory:   
 
 Sponsor:  OGD/CDER/FDA,  
 
 
 
 
 
 
Clinical Facility  
 Designated, Local 
Institutional Review 
Board (IRB)  Review 
and Oversight :  
 
 
 
 
Bioa nalytical 
Facility:    
  

 BPS[LOCATION_003] Protocol Number : 2521  
Protocol Version Number:  3.0, Date: Jun 22, [ADDRESS_169912]. Artan Markollari, M.D.  
BioPharma Services [LOCATION_003] Inc. 
 
 
 Date ( Mmm dd, yyyy)  
 

 BPS[LOCATION_003] Protocol Number : 2521  
Protocol Version Number:  3.0, Date: Jun 22, 2021 
Tacrolimus Capsule  
Fasting C onditions  
 
Page 12 of 68 
1.0 SYNOPSIS  
Title:  A Single Dose, Open -Label, Randomized, Four -Way Crossover, Fully Replicate, 
Bioequivalence Study of Generic Tacrolimus Capsules and Prograf¬Æ Capsules in 
Healthy Volunteers under Fasting Conditions . 
Objective:  The objective of this study is to investigate  the bioequivalence of Tacrolimus 1 mg 
capsules   and Prograf¬Æ 1 mg capsules  
in healthy male and non -pregnant , non- lactating  female volunteers under fasting  
conditions.  
Experimental Design : A single -dose, randomized, open -label, fully replicate crossover,  four-period, two-
treatment , two-sequence , bioequivalence study.  
Study Rationa le:  This is  an in-vivo study  to investigate the bioequivalence  of generic tacrolimus and its 
reference listed drug (RLD). The outcome of this study will help further the Agency‚Äôs  
understanding about pharmacokinetic (PK) performance of tacrolimus in a healthy 
volunteer population  and improve review standards for bioequivalence of narrow 
therap eutic index (NTI) drug s. 
Study Population:  72 subjects, including 8 standbys, will be enrolled to ensure dosing of approximately 
64 subjects.  The subjects may  be dosed in more than one cohort . 
 Healthy male and non -pregnant, non -lactating female volunteers, 1 8 - 59 years of age , 
inclusive , with a body mass index (BMI) within 18.5-33 .0 kg/m2, inclusive.  
Test Drug ( T): Tacrolimus 1 mg capsules (  
Reference Drug ( R): Prograf¬Æ 1 mg capsules  
Treatment:  1 √ó 1 mg capsules in each study period  
Duration of 
Confinement:  From at least [ADDRESS_169913]-dose, for a total of 
approximately  84 hours for each study period.  
Washout:  At least 14 days between each dosing.  
Safety Monitoring:  ‚Ä¢ Vital signs (blood pressure [BP] and heart rate [HR]) will be obtained at pre -
dose and at 1, 2, 4, 6, 12 , 24, 48 and 72  hours after dosing in each study 
period.  
‚Ä¢ All tests in Appendix B  at screening , and selected tests at each period check -
in and post -study.  
‚Ä¢ The PI/Sub -Investigator will be present from approximately [ADDRESS_169914] is dosed in each 
study period. The PI/Sub -Investigator will remain on -call throughout the 
duration of the study.  
COVID -19 prevention 
and control:  ‚Ä¢ Temperature , pulse ox imetry  and respi[INVESTIGATOR_148235], at 
each check -in, at pre -dose, at 6- and [ADDRESS_169915] dose, then at every 12 hours until 
discharge at each study period , at return visits  and at end of study (EOS) visit.   

 BPS[LOCATION_003] Protocol Number : 2521  
Protocol Version Number:  3.0, Date: Jun 22, 2021 
Tacrolimus Capsule  
Fasting C onditions  
 
Page 13 of 68 
‚Ä¢ A COVID -19 symptom check and COVID -19 questionnaire will also be completed 
at screening, at each check -in, at return visits  and at EOS visit.  
‚Ä¢ If applicable,  a locally available test for SARS -CoV -2 will be performed at each 
period check -in. 
Type of Vacutainer  Pre-chilled K 2EDTA Vacutainer ¬Æ, 4 mL  
Blood Sampling Time 
points:  28 PK Timepoints: Pre -dose (0 hour) and at 0.25, 0.50, 0.75, 1.00, 1.25, 1.50, 1.75, 
2.00, 2.25, 2.50, 2.75, 3.00, 3.50, 4.00, 5.00, 6.00, 8.00, 10.00, 12.00, 16.00, 24.00, 
36.00, 48.00, 72.00, 96.00, 120.00 and 144.00 hours after study drug dosing in each  
study period.  
Total Blood Volume:  Approximately [ADDRESS_169916]- study procedures  and the selected laboratory testing at each study period . 
Analyte(s) to be 
measured:  Whole blood samples will be assayed for tacrolimus using a validated analytical 
method according to the principles of Good Laboratory Practice.  
Statistical Analysis:  
 
 
 The ln -transformed PK parameters  AUC 72, AUC t, AUC inf and C max will be analyzed 
using both an unscaled average bioequivalence procedure and a reference -scaled 
average bioequivalence procedure.  
 
Determination of  the Within- subject Standard Deviation of the Test and 
Reference Products (  ùë∫ùë∫ùëæùëæùëæùëæ and ùë∫ùë∫ùëæùëæùëæùëæ ) for the PK Parameters AUC 72, AUC t, AUC inf 
and C max 
 
Reference Scaled Average Bioequivalence Procedure  
The 95% upper confidence bound for  will be determined for the 
ln-transformed PK parameters AUC 72, AUC t, AUC inf and C max using a PROC MIXED 
model in SAS.  
 
Unscaled Average Bioequivalence Procedure  
The 90% Confidence Intervals (CI) for the Test/Reference ratios of geometric means 
for the PK parameters AUC 72, AUC t, AUC inf and C max will be calculated using a PROC 
MIXED model in SAS.   
 
Tmax, Lambda and T 1/2 will be analyzed using an un -scaled procedure.  
 
Calculation of the 90% CI for the  Ratio of the Within -subject Standard Deviation 
of Test Product to  Reference Product  (ùùàùùàùëæùëæùëæùëæ/ ùùàùùàùëæùëæùëæùëæ) 
The 90% confidence interval of the ratio of the within subject standard deviation of 
test product to reference product (ùùàùùàùëæùëæùëæùëæ/ ùùàùùàùëæùëæùëæùëæ) will be calculated for tacrolimus.  
 
Bioequivalence 
Criteria:  
 
 
 To establish bioequivalence, all the following conditions for individual PK 
parameter(s) AUC 72and C max must be met : 
‚Ä¢ The 90% CI for the Test/Reference ratios of geometric means are completely 
contained within 80.00% -125.00%.  2 2) (WR R T SŒ∏¬µ¬µ ‚àí‚àí
 BPS[LOCATION_003] Protocol Number : 2521  
Protocol Version Number:  3.0, Date: Jun 22, 2021 
Tacrolimus Capsule  
Fasting C onditions  
 
Page 14 of 68 
‚Ä¢ The 95% upper confidence bound f or  should be less than 
or equal to 0.  
‚Ä¢ The upper limit of the 90% confidence interval for the Test/Reference ratio of 
the within -subject standard deviation  (ùùàùùàùëæùëæùëæùëæ/ ùùàùùàùëæùëæùëæùëæ) is less than or equal to 2.5.  
 
  2 2) (WR R T SŒ∏¬µ¬µ ‚àí‚àí
 BPS[LOCATION_003] Protocol Number : 2521  
Protocol Version Number:  3.0, Date: Jun 22, 2021 
Tacrolimus Capsule  
Fasting C onditions  
 
Page 15 of 68 
2.0 TABLE OF STUDY PROCEDURES  
 
 
Procedure/Activity  Time points  
Visit [ADDRESS_169917] -
Study/  
EOS^ 
Written informed 
consent  X       
Drugs of Abuse  X X      
Alcohol Test  X X      
Pregnancy (hCG) 
Test*  X X      
Vital Signs (BP & HR)  X X Xa Xa Xa Xa X 
Safety measures for 
COVID -19# (Symptom 
Check, Temperature, 
Pulse Oximetry and 
RR) X X X X X X X  
SARS- CoV-2 Testc  X      
BMI X       
Laboratory Testing‚∏∏ 
(Appendix B)  X X     X 
ECG X       
Inclusion/Exclusion 
Assessment  X Xb      
Restrictions 
Compliance Check   Xd Xd Xd Xd Xd  
Physical Exam  X       X 
Tacrolimus Capsule 
Administration    X X X X  
PK Sampling    Xe Xe Xe Xe  
Adverse Event 
Reporting   Xf Xf Xf Xf Xf X 
 BPS[LOCATION_003] Protocol Number : 2521  
Protocol Version Number:  3.0, Date: Jun 22, 2021 
Tacrolimus Capsule  
Fasting C onditions  
 
Page 16 of 68 
Meals  Xg Xg Xg Xg Xg  
^ EOS with one -week ¬±3 days window.  
* Serum pregnancy test at screening and urine pregnancy test at each period check -in. 
# Temperature , pulse oximetry and respi[INVESTIGATOR_148235], at each check -in, at 
pre-dose, at 6- and [ADDRESS_169918] dose , then at every 12 hours  until discharge  at each study period, at 
return visits  and at EOS  visit. A COVID -19 symptom check, and COVID -19 questionnaire will also 
be completed at screening, at each check -in, at return visits and at EOS visit.   
‚∏∏ All tests in Appendix B  at screening , and selected tests at each check -in and at EOS  (details in 
Appen dix A  and Appendix B ). 
a- Vital signs measurements (BP and HR) to be obtained at pre -dose and at 1, 2, 4, 6, 12 ,24, 48 and 72 
hours after dosing in each study period.  
b Only at check -in for the period 1.  
c- At each period check -in, if applicable . 
d- Confirmed at check -in and each return visits , if applicable.  
e- PK sampling: Pre -dose (0 hour) and at 0.25, 0.50, 0.75, 1.00, 1.25, 1.50, 1.75, 2.00, 2.25, 2.50, 2.75, 
3.00, 3.50, 4.00, 5.00, 6.00, 8.00, 10.00, 12.00, 16.00, 24.00, 36. 00, 48.00, 72.00, 96.00, 120.00 and 
144.00 hours after study drug dosing in each study period.  PK sampling at 96, 120 and 144 hours 
will be collected during  outpatient  return visit s.  
f- Pre-dose conditions at Period 1 check -in and each return visit , if applicable.  AEs will be monitored 
throughout the study.  
g- Meals will be served at  the scheduled times during confinement prior to dosing and at approximately 
4.5, 9.5, 13.5, 24.5, 28.5, 33.5, 37.5, 48.5, 52.5, 57.5  and 61.5 hours after dosing.  
 
 
 BPS[LOCATION_003] Protocol Number : 2521  
Protocol Version Number:  3.0, Date: Jun 22, 2021 
Tacrolimus Capsule  
Fasting C onditions  
 
Page 17 of 68 
3.0 INTRODUCTION: BACKGROUND  INFORMATION AND SCIENTIFIC 
RATIONALE  
3.1 Background Information  
Tacrolimus, a calcineurin inhibitor (CNI), has been widely used in solid organ and 
bone marrow transplants for more than two decades.  When an organ is transplanted 
between a donor and a genetically non identical recipi[INVESTIGATOR_841], the recipi[INVESTIGATOR_841]‚Äôs immune 
system may recognize the transplant ‚Äúforeign‚Äù and can trigger humoral immune 
response by [CONTACT_148258] T cells, B cells, and macrophages 
causing transplant rejection. Calcineurin , a calcium -dependent phosphatase, is  
instrumental for signal transduction for activation of T cell and B cell, which in turn 
cause production of autoinflammatory cytokines such as such as interleukin 2 (IL -
2), tumor necrosis factor -alpha (TNF -Œ±), and interferon -gamma (IFN -Œ≥). CNIs 
prevents the dephosphorylation and translocation of various factors such as the 
nucle ar factor of activated T -cells (NF -AT), and nuclear factor kappa -light-chain 
enhancer of activated B -cells (NF -Œ∫B), thereby [CONTACT_148259] T cells and expression of 
autoinflammatory cytokines. This mechanism of action results in 
immunosuppression and prevents organ rejection. T acrolimus is one of the widely 
used CNI immunosuppressant s in liver and kidney transplant patients  [1]. 
 
Oral bioavailability of tacrolimus is low, ranged from 11.2 to 19.1% in previous 
studies in adult kidney recipi[INVESTIGATOR_840]. The limited oral bioavailability of tacrolimus 
could be attributed to-  
‚Ä¢ Extensive metabolism through CYP3A4 and 3A5  enzymes  which are 
abundantly expressed in gut  [1],  
‚Ä¢ Poor oral absorption of the drug resulting from poor aqueous solubility [1].  
 
Optimum tacrolimus bioavailability is critical for - 
i. Achieving d esired clinical endpoint: The trough blood concentrations are 
signif icantly related to clinical endpoints, i.e.,  there was a significant 
correlation between increased trough concentration and decreased risk of 
acute rejection  and vice versa [2] . 
ii. Minimizing acute toxicity: Long term use of tacrolimus is associated with 
nephrotoxicity. Study showed monitoring trough tacrolimus whole blood 
concentrations below 15 ng/mL  decreased the occurrence of nephrotoxicity  
[3]. 
 
To enhance the oral bioavailability intricate formulation strategies have been 
studied. One such strategy in formulating tacrolimus in to amorphous solid 
dispersions (ASD). In ASDs , the amorphous form of the drug, which is believed to 
have increased solubility compared to crystalline form, is stabilized with the aid of 
a polymer. Currently, Prograf¬Æ and the six approved generic products referencing 
Prograf¬Æ are being formulated using ASD strategy. There are different 
 BPS[LOCATION_003] Protocol Number : 2521  
Protocol Version Number:  3.0, Date: Jun 22, [ADDRESS_169919] dissolution, 
precipi[INVESTIGATOR_332], and ultimately in vivo performances are poorly understood. For 
example, amorphous tacrolimus can be conve rted to crystalline tacrolimus during 
manufacture and/or storage, which may lead to decreased solubility and thereby 
[CONTACT_148260]. This is undesirable as blood concentration is tied to 
therapeutic performance [ 1].  
 
There are concern s in the transplant community that generic ASDs may not perform 
similarly to the brand ASD. To this end, the Office of Generic Drugs aims to 
evaluate BE of one of the generic products (generic from Acord) which showed 
likely inequivalent performance  in vitro and in vivo in a preclinical setting  [4, 5] . 
3.[ADDRESS_169920]  in comparison with that of its reference listed drug (RLD). The outcome of 
this study will help advance  the Agency‚Äôs understanding about the generic 
tacrolimus product ‚Äôs pharmacokinetic (PK) performance in healthy volunteer 
population and improve review s tandards for bioequivalence of NTI drugs.   
3.[ADDRESS_169921] Information  
PROGRAF¬Æ [6] 
 
Prograf¬Æ (tacrolimus) capsule is indicated for the prophylaxis of organ rejection in 
adult and pediatric patients receiving allogeneic kidney, liver , and heart transplant s, 
in combination with other immunosuppressants . 
 
Mechanism of Action  
 
Tacrolimus binds to an intracellular protein, FKBP -12. A complex of tacrolimus -
FKBP -12, calcium, calmodulin, and calcineurin (a ubiquitous mammalian 
intracellular enzyme) is then formed, after which the phosphatase activity of 
calcineurin is inhibited. Suc h inhibition prevents the dephosphorylation \  of various 
factors such as the nuclear factor of activated T -cells (NF -AT), and nuclear factor 
kappa -light-chain enhancer of activated B -cells (NF -Œ∫B). This dephosphorylation, 
in turn, prevents the translocation of these factors to the nucleus , leading to 
decreased activity and of genes coding for many cytokines.  Tacrolimus inhibits the 
expression and/or production of several cytokines that include interleukin (IL)- 1 
beta, IL -2, IL -3, IL -4, IL -5, IL -6, IL -8, IL -10, gamma interferon, tumor necrosis 
factor -alpha, and granulocyte macrophage colony- stimulating factor. Tacrolimus 
also inhibits IL -2 receptor expression and nitric oxide release, induces apoptosis and 
production of transforming growth factor beta that c an lead to immunosuppressive 
 BPS[LOCATION_003] Protocol Number : 2521  
Protocol Version Number:  3.0, Date: Jun 22, 2021 
Tacrolimus Capsule  
Fasting C onditions  
 
Page 19 of 68 
activity. The net result is the inhibition of T -lymphocyte activation and proliferation, 
as well as T -helper -cell-dependent B -cell response (i.e., immunosuppression). 
 
Pharmacokinetics  
 
Tacrolimus activity is primarily due to the parent drug. The pharmacokinetic 
parameters (mean ¬± S.D.) of tacrolimus have been determined following intravenous 
(IV) and/or oral (PO) administration in healthy volunteers , and also in kidney, liver, 
and heart transplant patients . 
 
Population  N Route 
(Dose)  Parameters  
Cmax 
(ng/mL) Tmax 
(hr) AUC 
(ng‚Ä¢hr/mL
) t1/2 (hr) CL 
(L/hr/kg)  V 
(L/kg)  
Healthy 
Volunteers  8 IV (0.025 
mg/kg/4 hr)  * * 652 ‚Ä† ¬± 156 34.2 ¬± 
7.7 0.040 ¬± 
0.009  1.91 ¬± 
0.31 
30 PO (5 mg) 
(granules)  35.6 ¬± 10.9  1.3 ¬± 
0.5 320 ‚Ä† ¬± 164  32.1 ¬± 
5.9 ‚Ä° ‚Ä° 
PO (5 mg) 
(capsules)  28.8 ¬± 8.9  1.5 ¬± 
0.7 266 ‚Ä† ¬± 95 32.3 ¬± 
8.8 ‚Ä° ‚Ä° 
 
Due to inter -subject variability in tacrolimus pharmacokinetics, individualization of 
the dosing regimen is necessary for optimal therapy. Pharmacokinetic data indicate 
that whole blood concentrations rather than plasma concentrations serve as the more 
appropriate sampling compartment to describe tacrolimus pharmacokinetics.  
 
Absorption  
Absorption of tacrolimus from the gastrointestinal tract after oral administration is 
incomplete and variable. The absolute bioavailability of tacrolimus was 17 ¬± 10% 
in adult kidney transplant patients (N = 26), 22 ¬± 6% in adult liver transplant patients 
(N = 17), 23 ¬± 9% in adult heart transplant patients (N = 11) and 18 ¬± 5% in healthy 
volunteers (N = 16). 
 
A single dose trial conducted in 32 healthy volunteers established the 
bioequivalence of the 1 mg and 5 mg capsules. Another single dose trial in 32 
healthy volunteers established the bioequivalence of the 0.5 mg and 1 mg capsules. 
Tacrolimus maximum blood concentrations (C max) and area under the curve (AUC) 
appeared to increase in a dose- proportional fashion in 18 fasted healthy volunteers 
receiving a single oral dose of 3, 7, and 10 mg. 
 
In 18 kidney transplant patie nts, tacrolimus trough concentrations from 3 to 30 
ng/mL measured at [ADDRESS_169922] -dose (C min) correlated well with the AUC 
(correlation coefficient 0.93). In 24 liver transplant patients over a concentration 
range of 10 to 60 ng/mL, the correlation coe fficient was 0.94. In 25 heart transplant 
patients over a concentration range of 2 to 24 ng/mL, the correlation coefficient was 
0.89 after an oral dose of 0.075 or 0.15 mg/kg/day at steady state.  
 
 BPS[LOCATION_003] Protocol Number : 2521  
Protocol Version Number:  3.0, Date: Jun 22, 2021 
Tacrolimus Capsule  
Fasting C onditions  
 
Page 20 of 68 
Prograf¬Æ granules are indicated for pediatric patients who have difficulty 
swallowing Prograf¬Æ capsules. In a healthy volunteer adult study, the systemic 
exposure to tacrolimus (AUC) for Prograf¬Æ Granules was approximately 16% 
higher than that for Prograf¬Æ capsules when administered as single doses. Hence, i f 
pediatric patients are  converted between formulations  (capsules to granules or 
granules to capsules) , therapeutic drug monitoring must be performed , and dose 
adjustments made to ensure that systemic exposure to tacrolimus is maintained.  
 
Food Effects  
The rate and extent of tacrolimus absorption were greatest under fasted conditions. 
The presence and composition of food decreased both the rate and extent of 
tacrolimus absorption when administered to [ADDRESS_169923] pronounced with a high -fat meal (848 kcal, 46% fat): mean 
AUC and Cmax were decreased 37% and 77%, respectively; T max was lengthened 5-
fold. A high- carbohydrate meal (668 kcal, 85% carbohydrate) decreased mean AUC 
and mean C max by 28% and 65%, respectively.  
 
In healthy volunteers (N = 16), the time of the meal also affected tacrolimus 
bioavailability. When given immediat ely following the meal, mean C max was 
reduced 71%, and mean AUC was reduced 39%, relative to the fasted condition. 
When administered 1.5 hours following the meal, mean C max was reduced 63%, and 
mean AUC was reduced 39%, relative to the fasted condition. 
 
In 11 liver transplant patients, P rograf¬Æ administered 15 minutes after a high fat (400 
kcal, 34% fat) breakfast, resulted in decreased AUC (27 ¬± 18%) and Cmax (50 ¬± 
19%), as compared to a fasted state.  
 
Prograf¬Æ capsules should be taken consistently every day either with or without food 
because the presence and composition of food decreases the bioavailability of 
Prograf¬Æ. 
 
Distribution  
The plasma protein binding of tacrolimus is approximately 99% and is independent 
of concentration over a range of 5- 50 ng/ mL. Tacrolimus is bound mainly to albumin 
and alpha -1-acid glycoprotein and has a high level of association with erythrocytes. 
The distribution of tacrolimus between whole blood and plasma depends on several 
factors, such as hematocrit, temperature at the time of plasma separation, drug 
concentration, and plasma protein concentration. In a U.S. trial, the ratio of whole 
blood concentration to plasma concentration averaged 35 (range 12 to 67).  
 
Metabolism  
Tacrolimus is extensively metabolized by [CONTACT_55316] -function oxidase system, 
primarily the cytochrome P -450 system (CYP3A). A metabolic pathway leading to 
the formation of 8 possible metabolites has been proposed. Demethylation and 
 BPS[LOCATION_003] Protocol Number : 2521  
Protocol Version Number:  3.0, Date: Jun 22, [ADDRESS_169924] the same activity as tacrolimus.  
 
Excretion  
The mean clearance following IV administration of tacrolimus is 0.040, 0.083, 0.053, and 0.051 L/hr/kg in healthy volunteers, adult kidney transplant patients, adult liver transplant patients, and adult heart transplant patients, re spectively. In 
man, less than 1% of the dose administered is excreted unchanged in urine.  In a mass balance study of IV -administered radiolabeled tacrolimus to 6 healthy 
volunteers, the mean recovery of radiolabel was 77.8 ¬± 12.7%. Fecal elimination accou nted for 92.4 ¬± 1.0% and the elimination half -life based on radioactivity was 
48.1 ¬± 15.9 hours whereas it was 43.5 ¬± 11.6 hours based on tacrolimus concentrations. The mean clearance of radiolabel was 0.029 ¬± 0.015 L/hr/kg and clearance of tacrolimus was 0.029 ¬± 0.009 L/hr/kg. When administered PO, the mean recovery of the radiolabel was 94.9 ¬± 30.7%. Fecal elimination accounted for 92.6 ¬± 30.7%, urinary elimination accounted for 2.3 ¬± 1.1% and the elimination half -
life based on radioactivity was 31.9 ¬± 10.5 hours whereas it was 48.4 ¬± 12.3 hours based on tacrolimus concentrations. The mean clearance of radiolabel was 0.226 ¬± 
0.116 L/hr/kg and clearance of tacrolimus was 0.172 ¬± 0.088 L/hr/kg.  
4.0 STUDY OBJECTIVE  
4.1 Study Objective 
The objective of this study is  to investigate  the bioequivalence of Tacrolimus  1 mg 
capsules  and Prograf
¬Æ 1 mg capsules  
in healthy male and non-pregnant , non- lactating  female volunteers under fasting  
condition. 
 
5.0 STUDY DESIGN 
5.1 Discussion of Study Design 
This is a single -dose, randomized, open- label, four- period, two- sequence, two -
treatment, single -center , crossover, bioequivalence study of tacrolimus 1 mg 
capsules   and Prograf¬Æ 1 mg capsules  
under fasting conditions.  
 
FDA has concluded that tacrolimus is a NTI drug based on the following evidence:  
- The range between tacrolimus therapeutic and toxic tacrolimus whole blood concentrations is narrow;  

 BPS[LOCATION_003] Protocol Number : 2521  
Protocol Version Number:  3.0, Date: Jun 22, 2021 
Tacrolimus Capsule  
Fasting C onditions  
 
Page 22 of 68 
- Some t acrolimus toxicities are serious and/or irreversible;  
- Subtherapeutic tacrolimus concentrations may lead to morbidity/mortality 
associated with graft rejection;  
- Tacrolimus requires individual dose titration to achieve a satisfactory 
balance between maximizing efficacy and minimizing serious dose-
related toxicity; Therapeutic drug monitoring is routinely employed to 
facilitate tacrolimus dose titration; and  
- Tacrol imus has small to medium within subject variability.  
 
This study is designed based on FDA draft guidance on Tacrolimus capsule (revised 
on Dec 2012) [ 7]. The bioequivalence assessment will be based on the 
recommendation from FDA for NTI drug.  
5.1.1 Screening  (Visit 1)  
Subjects will review ICF and document their consent by [CONTACT_148261].  
 
Screening procedures will be conducted within thirty  (30) days prior to dosing in 
Period 1. The Principal Investigator (PI)/Sub -Investig ator will review all screening 
results/data to assess eligibility of each potential subject.   In case of an unforeseeable 
delay, a selected safety screening test may be repeated  at the PI‚Äôs discretion . 
The Screening procedures will include (but not limited to): COVID- 19 prevention 
and control measures, collection of demographic data, medical and medication 
histories, physical examinations, body measurements (height and weight for Body 
Mass Index [BMI] calculation), vital signs ( seated blood pressure [BP], heart rate 
[HR], temperature, respi[INVESTIGATOR_697] [RR] and pulse oximetry), electrocardiogram 
(ECG), hematology, biochemistry, serology, urinalysis, and urine screening for 
drugs of abuse, alcohol test and serum pregnancy test (female subjects only). For a 
complete listing of all tests to be performed, please refer to Appendix B -  Clinical 
Laboratory Assessment.   
 
 BPS[LOCATION_003] Protocol Number : 2521  
Protocol Version Number:  3.0, Date: Jun 22, 2021 
Tacrolimus Capsule  
Fasting C onditions  
 
Page 23 of 68 
5.1.2 Treatment Phase (Visit 2 to 14)  
[IP_ADDRESS] Study Period Check- in Procedures  (Visit 2, 6, 10  and 14)  
At check -in for each study period, subjects will be questioned about whether they 
have complied with the study restrictions  and will be asked about the COVID -[ADDRESS_169925]‚Äôs participation will be made by [CONTACT_978]/Sub -
Investigator and will be reported to  the Sponsor.  
Urine tests for drugs of abuse and a breath alcohol test will be performed on all 
subjects at each study period check- in. In addition, urine hCG testing will be 
performed on all female subjects at each study period check -in. 
The subject‚Äôs hemoglobin and hematocrit levels will be assessed by [CONTACT_978]/Sub-
Investigator regarding the subject‚Äôs continued participation. Male subjects having a 
hemoglobin level below 12.0 g/dL and/or hematocrit level below 36.0%  or a female 
subjects having hemoglobin level below 12.0 g/dL and/or hematocrit level below 
34.0% , the subjects will not be permitted to continue in the study unless deemed 
non-clinically significant (NCS) by [CONTACT_976]/Sub -Investigator.  
Clinical staff reserves the right to conduct random testing (urine drugs of abuse, 
urine hCG [females only], or alcohol) on any subject at any time during the study to 
ensure subject compliance and/or safety. Any subject with a positive test for urine 
drugs of abuse, alcohol or urine hCG (females only) will be dismissed  immediately 
from the study.  
 
[IP_ADDRESS] Study Treatment  
Tacrolimus capsules will be studied using a fully replicate crossover design in  72 
healthy male and non- pregnant, non- lactating female volunteers, who will receive a  
single  oral dose of 1 √ó 1 mg capsule of each tacrolimus under fasting conditions. For 
each treatment, safety assessments and monitoring will be performed for the 
duration of confinement and PK assessments for up to  144 hours after each 
tacrolimus administration , as listed  Section 2 ‚Äì Table of Study Procedures . Adverse 
event(s) (AEs ) will be monitored throughout the study. There will be at least a 14 -
day washout period between each study period. Based on the half -life of tacrolimus 
capsule, this time -period  is adequate to  avoid drug carry -over from the preceding 
treatments. Blood samples will be collected at p re-dose (0 hour) and at 0.25, 0.50, 
0.75, 1.00, 1.25, 1.50, 1.75, 2.00, 2.25, 2.50, 2.75, 3.00, 3.50, 4.00, 5.00, 6.00, 8.00, 
10.00, 12.00, 16.00, 24.00, 36.00, 48.00, 72.00, 96.00, 120.00 and 144.00 hours after 
study drug dosing in each study period.  
 BPS[LOCATION_003] Protocol Number : 2521  
Protocol Version Number:  3.0, Date: Jun 22, [ADDRESS_169926]-Study [ End-of-Study  (EOS)] /Early Termination  
Clinical laboratory tests (hematology, serum chemistry and urinalysis), as per 
Appendix B ‚Äì Clinical Laboratory Assessment , will be performed at the end of the 
study or after withdrawal/dismissal of a subject from the study.  
At the end of the study or after withdrawal/dismissal of a subject from the study , a 
symptom- directed physical exam wit h the possibility for a full physical exam if 
deemed necessary by [CONTACT_978]/Sub -Investigator including vital signs ( BP, HR, 
temperature , pulse oximetry and RR) will be conducted unless the subject is lost to 
follow up. 
A follow up phone call will be made about a week  ¬±[ADDRESS_169927] attempted phone call is unsuccessful, the second phone call will be attempted 5 
¬±[ADDRESS_169928] study participant via phone is unsuccessful, a registered letter will be sent 5 ¬±[ADDRESS_169929] will be approximately 12 weeks, including 
an approximately 30- day screening period and approximately 50 days for the 
treatment periods  with a follow-up phone call
. 
5.3 Randomization and Blinding 
In this study, the assignment of treatment groups  (simple randomization scheme) 
will be generated by a computer program designed and run in SAS¬Æ Version 9.4  
  
 
Subjects who meet the eligibility criteria will be randomly assigned equally into one of the following two sequence groups:  

 BPS[LOCATION_003] Protocol Number : 2521  
Protocol Version Number:  3.0, Date: Jun 22, [ADDRESS_169930] is scheduled to receive each treatment twice by [CONTACT_2054].  
Treatment T (Test): 1 √ó 1mg tacrolimus capsules  
Treatment R (Reference): 1 √ó 1mg Prograf¬Æ [ADDRESS_169931] access to the randomization scheme until the bioanalytical analysis is complete.  
 
6.0 STUDY POPULATION 
A required number of healthy male and non-pregnant , non-lactating  female  
volunteers, as intended for general population [ 9],
 aged between 18- 59 years of age , 
inclusive will be screened according  to the inclusion and exclusion criteria listed in 
Sections 7.2  and 7.3  to be sure that about 64 are randomized.  
To assure subjects‚Äô safety, eligibility will be assessed at the participating clinical site at the time of screening and upon entry into the clinic prior to first drug 
administration .   
 
7.[ADDRESS_169932] SELECTION AND WITHDRAWAL/TERMINATION  
7.[ADDRESS_169933] 48 subjects.  Subjects who are dosed will not be replaced.  The subjects 
may be dosed in more than one cohort to achieve the total required sample size.  

 BPS[LOCATION_003] Protocol Number : 2521  
Protocol Version Number:  3.0, Date: Jun 22, 2021 
Tacrolimus Capsule  
Fasting C onditions  
 
Page 26 of 68 
7.2 Inclusion Criteria  
Potential subjects meeting all of the following criteria may be included in the study: 
(medical/operative reports may be requested to support assessment, if necessary) : 
1. Males and female  volunteers, 18 -59 years of age  (inclusive).  
2. BMI that is within 18.5- 33.0  kg/m¬≤, inclusive.  
3. Healthy, according to medical history, ECG, vital signs, laboratory results 
and physical examination as determined by [CONTACT_978]/Sub -Investigator.  
4. Capable of giving written informed consent prior to receiving any study 
medication.  
5. Availability to volunteer for the entire study duration and willing to adhere 
to all protocol requirements.  
6. Smokers: Capable of refraining from smokin g for the duration of the 
confinement . 
7. Female subjects must  be non- pregnant, non- lactating and fulfill at least one 
of the following: 
‚Ä¢ Be surgically sterile for a minimum of 6 months  
‚Ä¢ Post-menopausal for a minimum of 12 months ; Menopause defined 
as 12 months of amenorrhea without any other obvious pathological 
or physiological cause.  
‚Ä¢ Agree to avoid pregnancy and use medically acceptable method of 
contraception from at least 30 days prior to the study until 30 days 
after the stud y has ended ( last study procedure).  
Medically acceptable methods of contraception include non- hormonal 
intrauterine device or double barrier method (foam or vaginal spermicidal 
suppository in conjunction with a male condom, diaphragm with spermicide 
in conjunction with a male condom). Abstinence as a method of 
contraception is acceptable if it is in line with the preferred and usual lifestyle 
of the study participant.  
 
If a female subject becomes pregnant during participation in the study or 
within  [ADDRESS_169934] tacrolimus administration  
(whichever was administered last), she must inform BPS[LOCATION_003] staff 
immediately . 
8. Males who are able to father children must agree to use medically acceptable 
methods of contraception and not to donate sperm during the study and for 
30 days after the end of the study.  
Medically acceptable methods of contraception include using a condom with 
a female partner of child -bearing potential who is using:  oral contraceptives, 
 BPS[LOCATION_003] Protocol Number : 2521  
Protocol Version Number:  3.0, Date: Jun 22, [ADDRESS_169935]‚Äôs partner becomes pregnant during his participation in the 
study or within [ADDRESS_169936] tacrolimus  
administration  (whichever was administered last) , he must inform BPS[LOCATION_003] 
staff immediately.  
7.3 Exclusion Criteria  
Potential subjects meeting any of the following criteria will be excluded:  
1. Known history a nd/or presence of any clinically significant hepatic (e.g., 
hepatitis, jaundice, hepatic failure, hepatic necrosis, hepatic encephalopathy, 
biliary tract diseases, cirrhosis), renal/genitourinary (e.g., urethral stricture, 
any renal impairment), gastrointe stinal, cardiovascular (e.g., hypotension 
including orthostatic hypotension, cor pulmonale , congenital long QT, 
congestive heart failure, brady arrhythmias ), cerebrovascular, pulmonary 
(e.g., chronic obstructive pulmonary disease, decreased respi[INVESTIGATOR_148236], 
hypoxia, pre -existing respi[INVESTIGATOR_2341]), endocrine (e.g., myxedema, 
hypothyroidism, adrenal cortical insufficiency), immunological, 
musculoskeletal (e.g., kyphoscoliosis), neurological (e.g., CNS depression 
or coma, increased cerebrospi[INVESTIGATOR_148237]), psychiatric (e.g., psychosis, 
depression, hallucinations, delirium tremens, suicidal thoughts or behavior), 
dermatological or hematological (e.g., thrombocytopenic purpura) disease or 
condition unless determined as not clinically significant by [CONTACT_978]/Sub -
Investigator . 
2. History or presence of any clinically significant gastrointestinal pathology 
(e.g., chronic diarrhea, inflammatory bowel disease), unresolved 
gastrointestinal symptoms (e.g. , diarrhea, vomiting), or other conditions 
known to interfere with the absorption, distribution, metabolism or excretion 
of the drug experienced within [ADDRESS_169937] tacrolimus  administration, 
as determined by [CONTACT_978] /Sub-Investigator.  
3. Systolic blood pressure outside 90- 130 mmHg, inclusive, and diastolic blood 
pressure outside 55- 80 mmHg, inclusive, and heart rate between 50- 100 
bpm, inclusive, unless deemed otherwise by [CONTACT_978]/Sub- Investigator.  
4. QTc interval ‚â• 440 milliseconds for males and ‚â• 460 milliseconds for 
females, unl ess deemed otherwise by [CONTACT_978]/Sub -Investigator. 
5. Abnormal clinical laboratory values unless values are deemed by [CONTACT_978]/Sub-
Investigator as ‚ÄúNot Clinically Significant‚Äù.  
6. Abnormal vital signs (blood pressure [BP] , heart rate [HR], respi[INVESTIGATOR_697] 
[RR] , pulse oximetry  and temperature)  measurements,  unless deemed 
otherwise by [CONTACT_978]/Sub -Investigator. 
 BPS[LOCATION_003] Protocol Number : 2521  
Protocol Version Number:  3.0, Date: Jun 22, [ADDRESS_169938] 
dosing, as determined by [CONTACT_978] /Sub-Investigator. 
8. Presence of any significant physic al or organ abnormality as determined by 
[CONTACT_978] /Sub-Investigator.  
9. A positive test result for any of the following: HIV, Hepatitis B surface 
antigen, Hepatitis C, drugs of abuse (marijuana, amphetamines, barbiturates, 
cocaine, opi[INVESTIGATOR_858], phencyclidine and ben zodiazepi[INVESTIGATOR_1651]), and alcohol test. 
Positive serum or urine pregnancy test for female subjects.  
10. Known history or presence of:  
‚Ä¢ Alcohol abuse or dependence within one year prior to first study 
drug administration;  
‚Ä¢ Drug abuse or dependence;  
‚Ä¢ Hypersensitivity or idiosyncratic reaction to tacrolimus, its  
excipi[INVESTIGATOR_840], and/or related substances;  
‚Ä¢ Lymphoma and other malignancies (particularly of the skin);  
‚Ä¢ Bacterial, viral, fungal and protozoal infections (e.g., polyoma  virus -
associated nephropathy [ PVAN] due to BK virus infection, JC  virus 
associated progressive multifocal leukoencephalopathy [PML], Epstein 
Barr Virus (EBC) associated Post transplant lymphoproliferative 
disorder [PTLD], cytomegalovirus (CMV) infections associated CMV 
viremia and CMV disease);  
‚Ä¢ Tuberculosis;  
‚Ä¢ Posterior reversible encephalopathy syndrome (PRES); 
‚Ä¢ Pure red cell aplasia (PRCA); 
‚Ä¢ Gastrointestinal perforation; 
‚Ä¢ Hyperkalemia;  
‚Ä¢ Hypertension;  
‚Ä¢ Lactose intolerance, galactose intolerance, Lapp lactase deficiency or 
glucose -galactose malabsorption;   
‚Ä¢ Food allergies and/or presence of any dietary restrictions unless deemed 
by [CONTACT_978]/Sub- I as ‚ÄúNot Clinically Significant‚Äù.  
‚Ä¢ Severe allergic reactions (e.g. anaphylactic reactions, angioedema).  
11. History of i ntolerance to and/or difficulty with blood sampling through 
venipuncture. 
 BPS[LOCATION_003] Protocol Number : 2521  
Protocol Version Number:  3.0, Date: Jun 22, 2021 
Tacrolimus Capsule  
Fasting C onditions  
 
Page 29 of 68 
12. Abnormal diet patterns (for any reason) during the four weeks preceding the 
study, including fasting, high protein diets , vegan, etc.  
13. Individuals who have donated, in the days prior to first tacrolimus  
administration: 
‚Ä¢ 50-499 mL of blood in the previous 30 days;  
‚Ä¢ 500 mL or more or double red blood cell (‚ÄúPower red‚Äù) donation in 
the previous [ADDRESS_169939] tacrolimus 
administration . 
15. Hemoglobin level of 12.0 g/ dL or lower.  
16. Individuals who have participated in another clinical trial or who received 
an investigational drug within [ADDRESS_169940] 14 hours.  
18. Consumption of food or beverages containing grapefruit and/or pomelo 
within [ADDRESS_169941] study drug administration.  
19. Consumption of food or beverages containing caffeine/methylxanthines, 
poppy seeds and/or alcohol within [ADDRESS_169942] tacrolimus  
administration (except for allowed  contraceptive products).  
21. Use of any over -the-counter medications (including low -dose aspi[INVESTIGATOR_248], oral 
multivitamins, allergy medications , herbal and/or dietary supplements) 
within [ADDRESS_169943] tacrolimus  administration (except for 
spermicidal/barrier contraceptive products).  
22. Use of any enzyme- modifying drugs and/or other products, including 
inhibitors of cytochrome P450 (CYP) enzymes such as antifungals (e.g.,  
ketoconazole, itraconazole, fluconazole, voriconazole, posaconazole, 
clotrimazole), macrolide antibiotics (e.g. , erythromycin, clarithromycin, 
josamy cin), protease inhibitors (e.g., ritonavir, telaprevir [In civekTM], 
boceprevir [VictrelisTM], nelfinavir [Viracept¬Æ], saquinavir), calcium 
channel blockers (e.g. , verapamil, diltiazem, nifedipi[INVESTIGATOR_050], nicardipi[INVESTIGATOR_050]), 
nucleotide reverse transcriptase inhibitors (e.g., tenofovir), gastric acid 
suppressors/neturalizers (e .g., lansoprazole, omeprazole, cimetidine, 
cisapride, magnesium -aluminum hydroxide antacids), bromocriptine, 
cortisone, dapsone, ergotamine, gestodene, lidocaine, mephenytoin, 
miconazole, midazolam, nilvadipi[INVESTIGATOR_050], quinidine, tamoxifen, and triacetyl -
oleandom ycin and inducers of CYP enzymes such as anti -myobacterials 
(e.g., rifampin, rifabutin), antifungal agent (e.g.,  caspofungin), 
anticonvulsants (e.g. phenytoin, carbamazepi[INVESTIGATOR_050], phenobarbital), 
 BPS[LOCATION_003] Protocol Number : 2521  
Protocol Version Number:  3.0, Date: Jun 22, 2021 
Tacrolimus Capsule  
Fasting C onditions  
 
Page 30 of 68 
corticosteroids (e.g. prednisolone or methylprednisolone), metami zole, 
isoniazid and products containing St. John‚Äôs Wort in the previous [ADDRESS_169944] study drug administration.  
23. Use of medicines such as, mycophenolic acid (MPA) products, 
aminoglycosides, gyrase inhibitors, vancomycin, cotrimoxazole, NSAIDs, 
oral anticoagulants, or oral antidiabetics, ganciclovir, acyclovir, 
amphotericin B, ibuprofen, cisplatin, potassium supplements, potassium -
sparing diuretics (e.g. , amiloride, triamterene or spi[INVESTIGATOR_8407]), ACE 
inhibitors (for example, benazepril, enalapril, quinapril), statins (for 
example, atorvastatin, fluvastatin, simvastatin), angiotensin receptor 
blockers (for example, irbesartan, valsartan, azilsartan) , nefazodone, 
metoclopramide, danazol, and herbal products containing Schisandra 
sphenanthera extracts sh ould be avoided during treatment with tacrolimus 
in the previous [ADDRESS_169945] study drug administration.  
24. Use of any QT prolonging drugs (e.g., citalopram, chlorpromazine, 
haloperidol, methadone), amiodarone [CordaroneTM, NexteroneTM, 
PaceroneTM], immunosuppressive or immunomodulating therapi[INVESTIGATOR_014] (e.g. 
sirolimus [Rapamune¬Æ], c yclosporins [Gengraf¬Æ, Neoral¬Æ, and 
Sandimune¬Æ], antilymphocytic antibodies [e.g., basiliximab, daclizumab]) 
should be avoided during treatment with tacrolimus in the previous [ADDRESS_169946] study drug administration.  
25. Individuals having undergone any major surgery within 6 months prior to 
the start of the study, unless deemed otherwise by [CONTACT_976] /Sub-Investigator.  
26. Does not agree , to refrain from driving or operat ing heavy machinery if 
feeling dizzy or drowsy following tacrolimus  administration until full mental 
alertness is regained.  
27. Does not have a n ability to  fast for at least 14 hours.  
28. Recent history (within 8 weeks prior to screening) of travel to or emigration 
from any country with high incidence of tuberculosis.  
29. Temperature at visit is ‚â• 100.4 F (38.0¬∞C).  
30. Test positive for SARS -CoV- [ADDRESS_169947] two weeks as documented in the COVID -19 screening questionnaire  
 BPS[LOCATION_003] Protocol Number : 2521  
Protocol Version Number:  3.0, Date: Jun 22, [ADDRESS_169948] will sign and date the Informed Consent Form  (ICF) to confirm that co nsent 
has been obtained.  The subject will receive a copy of this document and the original 
will be filed in the subject binder.  In case of a screen failure, it will be filed 
separately in the designated binder.  
7.[ADDRESS_169949]‚Äôs continued participation will be re -
assessed by [CONTACT_978] /Sub-Investigator , Pharmacokinetic staff , and reported to the 
Sponsor . 
1. No food will be allowed from at least [ADDRESS_169950] 4 hours 
after dosing. Except for the 8 ¬± 0.[ADDRESS_169951]-dose. Water will 
be all owed/provided ad libitum  at all other times.  
2. No smoking will be permitted during confinement.  
3. Subjects will be required not to drive or operate heavy machinery as indicated in 
Section 7.3 . 
 
1 Adenovirus Type 4 and Type 7 vaccine  (Oral), Cholera vaccine, Ebola Zaire vaccine (Live), Influenza vaccine, 
Measles, Mumps, and Rubella Virus Vaccine (Live), Smallpox (Vaccinia) Vaccine (Live), Smallpox and 
Monkeypox vaccine (Live, Non-replicating), Typhoid Vaccine (Live Oral Ty21a), Yellow  Fever Vaccine and 
Zoster Vaccine (Live) . 
 BPS[LOCATION_003] Protocol Number : 2521  
Protocol Version Number:  3.0, Date: Jun 22, 2021 
Tacrolimus Capsule  
Fasting C onditions  
 
Page 32 of 68 
4. Subjects will be required  to limit exposure to sunlight and UV light by [CONTACT_148262] a sunscreen with a high protection factor during 
study participation until the study completion.  
5. Subjects will be required not to receive a vaccination (live attenuated vaccine) . 
Examples include (but are not limited to): Adenovirus Type 4 and Type 7 vaccine 
(Oral), Cholera vaccine, Ebola Zaire vaccine (Live), Influenza vaccine, Measles, 
Mumps, and Rubella Virus Vaccine (Live), Smallpox (Vaccinia) Vaccine (Live), 
Smallpox and Monkeypox vaccine (Live, Non- replicating), Typhoid Vaccine 
(Live Oral Ty21a), Yellow Fever Vaccine and Zoster Vaccine (Live)  during the 
study and until 30 days after the study has ended (last study procedure) . 
6. The consumption of alcohol of any kind (e.g., wine, beer, liquor, cocktails), 
products containing caffeine/methylxanthines (e.g., coffee, tea, chocolate, 
caffeine -containing soft drinks [ e.g. Coke, Pepsi, Red Bull] ) and poppy seeds 
containing products (poppy seed cake, cookies, bagels) wi ll be prohibited for [ADDRESS_169952] blood draw in each 
study period . 
7. The consumption of f oods and/or beverages containing grapefruit and/or pomelo 
(e.g., grapefruit, grapefruit juice, grapefruit candies, po melo, etc.) will be 
prohibited for [ADDRESS_169953] blood 
draw in the final study period.  
8. Any concomitant medication (prescription medications [e.g., prescription pi[INVESTIGATOR_3353], 
topi[INVESTIGATOR_148238], inhalants, sprays] or over -the-counter  such as low -dose 
aspi[INVESTIGATOR_248], allergy medications and oral multivitamins ), any herbal and/or dietary 
supplements will not be permitted for [ADDRESS_169954] drug administration.  
9. Any concomitant medication ( prescription  medications [e.g., prescription pi[INVESTIGATOR_3353], 
topi[INVESTIGATOR_148238], inhalants, sprays ] or over-the-counter) , any herbal 
and/or dietary supplements from the start of dosing of the study until the last 
blood draw in the final study period unless deemed otherwise by [CONTACT_978]/Sub-
Investigator for treatment of any adverse events (AEs) .  
Any use of  concomitant medication or herbal/dietary supplement during the 
restriction period for the restriction # 9 will be reported as soon as possible to the 
PI/Sub-Investigator , Pharmacokinetic staff and reported to the Sponsor. In each 
case, the decision whether to continue or discontinue the subject‚Äôs participation 
in the study will be made by [CONTACT_978]/Sub- Investigator and/or by [CONTACT_148263]. 
10. Use of any enzyme -modifying drugs and/or other products, including inhibitors 
of cytochrome P450 (CYP) enzymes such as antifungals (e.g., ketoconazole, 
itraconazole, fluconazole, voriconazole, posaconazole, clotrimazole), macrolide 
antibiotics (e.g., erythromycin, clarithromycin, josamycin), protease inhibitors 
(e.g., ritonavir, telapr evir [IncivekTM], boceprevir [VictrelisTM], nelfinavir 
[Viracept¬Æ], saquinavir), calcium channel blockers (e.g., verapamil, diltiazem, 
nifedipi[INVESTIGATOR_050], nicardipi[INVESTIGATOR_050]), nucleotide reverse transcriptase inhibitors (e.g., 
 BPS[LOCATION_003] Protocol Number : 2521  
Protocol Version Number:  3.0, Date: Jun 22, 2021 
Tacrolimus Capsule  
Fasting C onditions  
 
Page 33 of 68 
tenofovir), gastric acid suppressors/neturalizers (e.g., lansoprazole, omeprazole, 
cimetidine, cisapride, magnesium -aluminum hydroxide antacids), bromocriptine, 
cortisone, dapsone, ergotamine, gestodene, lidocaine, mephenytoin, miconazole, 
midazolam, nilvadipi[INVESTIGATOR_050], quinidine, tamoxifen, and triacetyl -oleandomycin and 
inducers of CYP enzymes such as anti -myobacterials (e.g., rifampin, rifabutin), 
antifungal agent (e.g., caspofungin), anticonvulsants (e.g., phenytoin, 
carbamazepi[INVESTIGATOR_050], phenobarbital), corticosteroids (e.g.,  prednisolone or 
methylprednisolon e), metamizole, isoniazid and products containing St. John‚Äôs 
Wort within [ADDRESS_169955] blood 
draw in the final study period.  
11. Use of medicines such as, mycophenolic acid (MPA) products, 
aminoglycosides, gyra se inhibitors, vancomycin, cotrimoxazole, NSAIDs, oral 
anticoagulants, or oral antidiabetics, ganciclovir, acyclovir, amphotericin B, 
ibuprofen, cisplatin, potassium supplements, potassium -sparing diuretics (e.g.,  
amiloride, triamterene or spi[INVESTIGATOR_8407]),  ACE inhibitors (for example, 
benazepril, enalapril, quinapril), statins (for example, atorvastatin, fluvastatin, 
simvastatin), angiotensin receptor blockers (for example, irbesartan, valsartan, 
azilsartan),  nefazodone, metoclopramide, danazol, and herbal products 
containing Schisandra sphenanthera  extracts should be avoided during treatment 
with tacrolimus within [ADDRESS_169956] blood draw in the final study period. 
12. Use of any QT prolonging drugs (e.g., citalopram, chlorpromazine, haloperidol, 
methadone), amiodarone [CordaroneTM, NexteroneTM, PaceroneTM], 
immunosuppressive or immunomodulating therapi[INVESTIGATOR_014] (e.g., sirolimus 
[Rapamune¬Æ], ciclosporins [Gengraf¬Æ, Neoral¬Æ, and Sandimune¬Æ], 
antilymphocytic antibodi es [e.g., basiliximab, daclizumab]) should be avoided 
during treatment with tacrolimus within [ADDRESS_169957] blood draw in the final study period. 
13. Physical activity: Subjects will remain awake for the first 4 hours following 
tacrolimus  administration . If a medical event (i.e. , AE) occurs, subjects may be 
placed in an appropriate position at that time. Subjects will be required to abstain 
from strenuous /vigorous  activities for the duration of the study period( s). When 
the subjects leave the clinic, they will be requested to refrain from strenuous 
physical activity until the completion of the 144- hour blood draw  in each study 
period.  
14. For [ADDRESS_169958] the content during this time.  
15. Additional study restriction for COVID -19 prevention and control:  
‚Ä¢ Subjects must be  willing to soci al distance, wear masks and practice hand 
hygiene while enrolled in the study  
 BPS[LOCATION_003] Protocol Number : 2521  
Protocol Version Number:  3.0, Date: Jun 22, 2021 
Tacrolimus Capsule  
Fasting C onditions  
 
Page 34 of 68 
‚Ä¢ Report to study staff in case of exposures to known or possible COVID -[ADDRESS_169959]‚Äôs participation in the study if:  
‚Ä¢ Any clinical adverse event (AE), laboratory abnormality, or other medical 
condition or situation occurs such that continu ed participation in the study 
would not be in the best interest of the subject.  
‚Ä¢ The subject meets an exclusion criterion (either newly developed or not 
previously recognized) that precludes further study participation. 
The cause, date and time of withdrawal or termination will be documented in the 
source documents and in the final study report. If a subject‚Äôs participation is 
terminated prematurely, the cause for the early termination date and time of the 
termination will be documented on the source documents and in the final study 
report.  
Subjects experiencing emesis within 3 hours (2 times median T max, 1.5 hour, reported 
in the label [ 6]) after dosing will be dismissed from the affected period in the study.  
Subjects experiencing 3 or more epi[INVESTIGATOR_148239] (diarrhea) after dosing will 
be allowed to stay in the study unless the PI/Sub- Investigator recommends the 
subject to be dismissed from the study due to safety reasons. All decisions will be 
made prior to the bioanalytical laboratory commencing bioa nalysis.  
 
Subjects who are dismissed or withdrawn from Period 1, may be eligible to return 
for Period 2  and/or Period 3 and/or Period 4, if deemed safe and appropriate by [CONTACT_1600]/Sub -Investigator. All subjects will be reviewed by [CONTACT_978] [INVESTIGATOR_148240]-entry. Subjects who are dismissed due to a Treatment -Emergent Adverse Event 
(TEAE) or non- compliance will not be eligible to return for Period 2  and/or Period 
3 and/or Period 4. 
 
Withdrawn and dismissed subjects who are returning for subsequent per iods are 
required to adhere to the study specific procedures (e.g.,  study restrictions). If a 
subject is withdrawn or dismissed following tacrolimus administration and will not 
be returning in subsequent periods (i.e., for Period  2 and/or Period 3 and/or P eriod 
4), these subjects are still r equired to adhere to the study restrictions with regards to 
the safety, prescription medication, over -the-counter medication, dietary and/or 
herbal supplements  for the expected duration of the restriction relevant to the  study 
period the subject withdrew or was dismissed from (where that period becomes the 
subject‚Äôs last study period) .  
 
Female subjects will be asked to adhere to the requirements of not becoming 
pregnant and using a medically acceptable method of contraception for 30 days after 
 BPS[LOCATION_003] Protocol Number : 2521  
Protocol Version Number:  3.0, Date: Jun 22, 2021 
Tacrolimus Capsule  
Fasting C onditions  
 
Page 35 of 68 
discontinuation from the study (if applicable). Male subjects who are able to father 
children will be asked to adhere to the requirements of using medically acceptable 
methods of contraception for 30 days after discontinuation in the study.  
This study may be suspended or prematurely terminated if there is sufficient 
reasonable cause.  Written notification, documenting the reason for study suspension 
or termination, will be provided by [CONTACT_148264], sponsor and regulatory authorities. If the study is prematurely 
terminated or suspended, the principal investiga tor will promptly inform the IRB 
and will provide the reason(s) for the termination or suspension.  
Circumstances that may warrant termination include, but are not limited to:  
‚Ä¢ Determination of unexpected, significant, or unacceptable risk to subjects. 
‚Ä¢ Insufficient adherence to protocol requirements.  
‚Ä¢ Data that are not sufficiently complete and/or evaluable.  
‚Ä¢ Determination of futility.  
Subjects whose participation in the study is discontinued (for any reason) will not 
be replaced.  If a subject withdraws or is dismissed from the study, a post -study 
symptom -directed physical exam with the possibility for a full physical exam if 
deemed necessary by [CONTACT_978]/Sub -Investigator  will be conducted and post -study 
testing will be completed, wher e possible.  
 
8.0 STUDY PROCEDURES  
All study assessments will be performed at the visits and time points outlined in the 
Table of Study Procedures ( Section 2.0 ). 
8.1  Demographics and Other Baseline Characteristics 
8.1.1 Demographics  
Demographics including  age ( date of birth  and years), sex, race, and ethnicity  will 
be recorded at screening.  
8.1.2 Medical History  
The complete medical history will include histor y of acute, chronic, or infectious 
disease s; surgical or oncologic histories; and any reported conditions affecting major 
body systems. All  findings on medical history will be evaluated by [CONTACT_978]/Sub -
Investigator  for clinical significance.   
8.1.3 Medication Histo ry 
All medications (prescription and non- prescription /OTC, herbal medications/natural 
health products, or investigational drugs) taken by [CONTACT_12539] 30 days 
prior to Screening will be  recorded in the source documentation as medication 
history.  
 BPS[LOCATION_003] Protocol Number : 2521  
Protocol Version Number:  3.0, Date: Jun 22, 2021 
Tacrolimus Capsule  
Fasting C onditions  
 
Page 36 of 68 
8.1.4 Clinical Laboratory Assessments  
Clinical laboratory assessments will be conducted at Screening , each period check-
in and at the EOS. All laboratory safety data will be reviewed by [CONTACT_978]/Sub -
Investigator  for clinical significance. Additional laboratory sa mples may be taken at 
the discretion of the PI/Sub -Investigator  (e.g., if the results of any tests fall outside 
reference ranges or clinical symptoms necessitate testing to ensure safety).  
 
Blood and urine samples collected  for clinical laboratory assessments will be  
processed and shipped according to the research site‚Äôs SOPs and instructions from 
the clinical laboratory.  
 
For a complete listing of all tests to be performed, please refer to Appendix B - 
Clinical Laboratory Assessment .  
8.[ADDRESS_169960] 4 -hours after dosing, subjects will be given 
standardized meals and caffeine/methylxanthine- free beverages at  approximately 
4.5, 9.5, 13.5, 24.5, 28.5, 33.5, 37.5, 48.5, 52.5, 57.[ADDRESS_169961] -dose. Water will be allowed/provided ad libitum  at 
all other times.  
8.[ADDRESS_169962] 10 hours, s ubjects will take their assigned formulation with 8 
¬± 0.[ADDRESS_169963] of subjects‚Äô safety, the following safety parameters will be assessed 
in all subjects.  
 BPS[LOCATION_003] Protocol Number : 2521  
Protocol Version Number:  3.0, Date: Jun 22, [ADDRESS_169964] will be completed by a clinic staff 
to document all history of exposure and history of symptoms related to COVID -19. 
The COVID- 19 questionnaire is provided in the  site‚Äôs COVID- [ADDRESS_169965] is provided in 
the site‚Äôs COVID- [ADDRESS_169966] dose, then at every 12 hours until discharge at 
each study period, at return visits and at EOS . Additional pulse oximetry and 
respi[INVESTIGATOR_148241]. The normal ranges of p ulse oximetry and respi[INVESTIGATOR_148242]: 
- a pulse oximeter reading of:  ‚â• 95%  
- a range of resting respi[INVESTIGATOR_148243] [ADDRESS_169967]. The sample collection and shipment will follow a specific procedure 
 BPS[LOCATION_003] Protocol Number : 2521  
Protocol Version Number:  3.0, Date: Jun 22, [ADDRESS_169968] positive for SARS -
CoV- 2 will be excluded from any subsequent study procedures. 
8.6 Vital Signs  
Vital signs ( BP and  HR) will be monitored at pre -dose and at 1, 2, 4, 6, [ADDRESS_169969] -Dose (all periods):  
Acceptable Range -  systolic blood pressure between 90- 130 mmHg, diastolic blood 
pressure between 55- 80 mmHg, inclusive, and heart rate between  50-100 bpm, 
inclusive.  
 
If the Investigator is not immediately available on site to assess out of range vital 
signs, the vital signs will be repeated up to two times. If vital signs are still outside 
of the acceptable range, the PI/Sub -Investigator will be informed , and PI/Sub -
Investigator will determine the appropriate course of action.  
 
Additional vital signs measurements will b e taken if deemed necessary by [CONTACT_1600]/Sub-Investigator. Blood draws will take precedence over vital signs 
measurements and other scheduled activities if the scheduled time of several 
activities is overlapped to each other  unless deemed necessary by [CONTACT_978]/Sub-
Investigator  or due to subject‚Äôs safety.  
8.7 ECG  
A 12 -lead ECG with rhythm strip will be performed  at screening, Additional 
measurements are not required during this study unless deemed necessary by [CONTACT_1600]/Sub -Investigator.  
8.8 Health Monitoring  
The PI/Sub -Investigator will be present approximately [ADDRESS_169970] is dosed in each study period. The PI/Sub-
Investigator will remain on -call throughout the duration of the study.  
Health monitoring wi ll be conducted throughout the study or as needed. Adverse 
events will be monitored throughout the study.  
8.[ADDRESS_169971].  
 
 BPS[LOCATION_003] Protocol Number : 2521  
Protocol Version Number:  3.0, Date: Jun 22, [ADDRESS_169972] - study 
procedures  and the selected laboratory testing 
at each study period . Approximately 520 mL of blood 
Type of Vacutainer  Pre-chilled K 2EDTA Vacutainer ¬Æ, 4 mL  
Blood Sampling Time Points2,3 Pre-dose (0 hour) and at 0.25, 0.50, 0.75, 1.00, 
1.25, 1.50, 1.75, 2.00, 2.25, 2.50, 2.75, 3.00, 
3.50, 4.00, 5.00, 6.00, 8.00, 10.00, 12.00, 
16.000, 24.000, 36.00, 48.00, 72.00, 96.00, 
120.[ADDRESS_169973] tube and the 
remaining whole blood (if any) will be aliquoted into a second tube. Polypropylene 
tubes w ill be pre -chilled and pre -labeled with at least the following information: 
Time -point, Protocol Number, Study Period, Aliquot Number, Matrix and Subject 
Number. The samples will be stored at - 20¬∫C ( -15¬∫C or colder) in a freezer pending 
shipment.  
Throughout sample collection, the samples will be maintained in an ice -bath until 
stored in the freezer.  
8.[ADDRESS_169974] been received by 
[CONTACT_85332], the second set of aliquots will then be shipped/delivered.  
All shipments will be accompanied by [CONTACT_148265]:  
                  
 
2 - Pre-dose samples to be obtained within 2 hours  prior to study drug administration . 
3 - The blood sample will be collected within ¬± 1 -hour window for the 96, 120 and 144 -hours time 
points.  
 BPS[LOCATION_003] Protocol Number : 2521  
Protocol Version Number:  3.0, Date: Jun 22, 2021 
Tacrolimus Capsule  
Fasting C onditions  
 
Page 40 of 68 
 
 
 
 
 
 
Clinic personnel will notify the bioanalytical laboratory prior to shipment by [CONTACT_648], fax or e -mail.  The bioanalytical laboratory will notify BPS [LOCATION_003] by [CONTACT_5640] e -mail or 
fax of confirmation of receipt of each aliquot.  
 
9.0 DRUG PRODUCTS  
9.1 Drug Information   
Table 9-1 Study Drugs Information 
 T (Test)  R (Reference)  
Drug Name:  [CONTACT_148283]¬Æ 
Strength:  1 mg 1 mg 
Dosage Form:  Capsules  Capsules  
Manufactured 
by/for:    
Dose:  1 √ó 1 mg 1 √ó 1 mg 
 
9.2 Labeling, Maintenance, and Retention  
Each investigational study drug will be labeled (in English) with a statement  
indicating that the drug is an investigational drug to be used only by a Qualified 
Investigator and will include but is not limited to: Drug  Name, Strength, Protocol 
Number, Sponsor‚Äôs  Name [CONTACT_1781], the recommended storage conditions for the 
drug, Expi[INVESTIGATOR_4061]/Retest Date  (when available) , and Lot/Batch Number. 
9.3 Drug Inventory 
The BPS[LOCATION_003] will supply sufficient quantities of the study drugs for the following: 
(1) completion of this study and (2) retention, as per applicable regulations. All drug supplies provided for this study will be stored in a secure area with restricted access, under controlled storage conditions described in the product package labelling, unless otherwise instructed per protocol.  
Records will be made of receipt and dispensing of tacrolimus  supplied.  

 BPS[LOCATION_003] Protocol Number : 2521  
Protocol Version Number:  3.0, Date: Jun 22, [ADDRESS_169975] common adverse reactions (‚â• 15%) were abnormal renal 
function, hypertension, diabetes mellitus, fever, CMV infection, tremor, 
hyperglycemia, leukopenia, infection, anemia, bronchitis, pericardial effusion, 
urinary tract  infection, constipation, diarrhea, headache, abdominal pain, insomnia,  
paresthesia, peripheral edema, nausea, hyperkalemia, hypomagnesemia, and  
hyperlipemia. [ 6]. 
 
The following serious adverse reactions  were also reported in the patients who  were 
tacrolimus users [ 6]: 
 
‚Ä¢ Lymphoma and Other Malignancies  
‚Ä¢ Serious Infections  
‚Ä¢ New Onset Diabetes After Transplant  
‚Ä¢ Nephrotoxicity  
‚Ä¢ Neurotoxicity 
‚Ä¢ Hyperkalemia  
‚Ä¢ Hypertension 
‚Ä¢ QT Prolongation  
‚Ä¢ Myocardial Hypertrophy  
‚Ä¢ Immunizations  
‚Ä¢ Pure Red Cell Aplasia  
 
COVID- [ADDRESS_169976] benefit to subjects, the knowledge that may result 
from the study may help with the development of generic formulations of tacrolimus  
and may enhance the regulatory review standards for equivalence of this category .  
 BPS[LOCATION_003] Protocol Number : 2521  
Protocol Version Number:  3.0, Date: Jun 22, 2021 
Tacrolimus Capsule  
Fasting C onditions  
 
Page 42 of 68 
11.0 SAFETY ASSESSMENT  
BioPharma Services [LOCATION_003] Inc. (BPS [LOCATION_003]) ensure the timely, accurate and complete 
reporting of safety information  in conformity with regulatory requirements . 
PI/Sub -Investigators at BPS[LOCATION_003] are responsible for monitoring the safety and for 
providing appropriate medical care for subjects who have entered this trial (i.e., from 
the signing of ICF onwards). In addition, the PI/Sub- Investigator remains 
responsible for following -up all AEs.  
Each subject will be carefully questioned and/or examined by [CONTACT_978]/Sub-
Investigator or a medically qualified delegate (i.e., authorized by [CONTACT_737], in 
a separate form, to record AEs) to obtain information regarding AEs. All AEs will 
be reported and documented as stated below . 
 
Any symptoms or positive tests related to COVID -19 will be documented as part of 
AEs reporting. This documentation applies from the time that volunteers receive the 
study drugs  until the completion of the end- of-study procedures.  
11.1 Definitions  
Adverse Event (AE)  ‚Äì is any untoward medical occurrence in clinical trial subject 
who are administered with any of study drugs and which does not necessarily have 
a causal relationship with this treatment. An adverse event can therefore be any 
unfavorable and unintended sign (e.g. an abnormal laboratory finding), symptom, 
or disease temporally associated with the use of a study dr ug, whether or not 
considered related to the study drug.  
 
Adverse Drug Reaction (ADR)  of study drug any of study drugs is any untoward 
and unintended response to any of study drugs related to any dose administered.  
 
Unexpected Adverse (Drug) Reaction ‚Äì is an adverse reaction, the nature or 
severity of which is not consistent with the applicable product information (e.g., 
Prescribing Information for an authorized product).  
 
Serious Adverse Event (SAE ) / Reaction  ‚Äì a serious adverse event (experience) or 
reaction is any untoward medical occurrence or effect that at any dose can:  
 BPS[LOCATION_003] Protocol Number : 2521  
Protocol Version Number:  3.0, Date: Jun 22, 2021 
Tacrolimus Capsule  
Fasting C onditions  
 
Page 43 of 68 
‚Ä¢ result in death, 
‚Ä¢ be life -threatening,  
‚Ä¢ require hospi[INVESTIGATOR_148244],  
‚Ä¢ result in persistent or significant disability or incapacity,  
‚Ä¢ cause a congenital anomaly/birth defect,  
‚Ä¢ be other medically important event that may not be immediately life -
threatening or result in death or hospi[INVESTIGATOR_148245] -listed outcomes.  
Suspected Unexpected Serious Adverse Reaction (S[LOCATION_003]R) ‚Äì is all suspected 
adverse reactions related to Prograf¬Æ and generic tacrolimus capsules which can 
occur in the concerned trial, and that are both unexpected and serious.  
Unan ticipated Problems ‚Äì The unanticipated problems involving risks to subjects 
or others to include, in general, any incident, experience, or outcome that meets all 
of the following criteria: 
‚Ä¢ unexpected in terms of nature, severity, or frequency given (a) the  research 
procedures that are described in the protocol -related documents, such as the 
IRB- approved research protocol and informed consent document; and (b) the 
characteristics of the subject population being studied;  
‚Ä¢ related or possibly related to participation in the research (‚Äúpossibly related‚Äù 
means there is a reasonable possibility that the incident, experience, or 
outcome may have been caused by [CONTACT_3459]); 
and 
‚Ä¢ suggests that the research places subjects or others at a greater risk of harm 
(including physical, psychological, economic, or social harm) than was 
previously known or recognized.  
Subjects will be instructed to inform clinic personnel of any untoward medical 
symptoms and/or events that may arise during the study.  
11.1.1 Treatment -emergent adverse events (TEA Es) 
Treatment emergent adverse events (TEAEs ) are undesirable events , not present 
prior to medical treatment , or an already present event  that worsens either in 
intensity or frequency following the treatment . A TEAE is an adverse event  that 
occurs only once treatment has started.  All TEAEs a nd all treatment emergent S AEs 
will be summarized.  
 
The PI/sub -I will be responsible for determining whether a TEAE is possibly related 
to the SARS -CoV- 2 and document accordingly.  
 BPS[LOCATION_003] Protocol Number : 2521  
Protocol Version Number:  3.0, Date: Jun 22, 2021 
Tacrolimus Capsule  
Fasting C onditions  
 
Page 44 of 68 
11.2 Characteristics of an Adverse Event  
11.2.1 Relationship to Study Drug 
The PI/Sub-Investigator will assess the relationship of all adverse reactions to the 
study drug, using the following scale:  
 
Probable  A clinical event, including laboratory test abnormality, with a 
reasonable time sequence to drug administration, unlikely to be 
attributed to concurrent disease or other drugs or chemicals, and 
which follows a clinically rea sonable response on withdrawal.  
Possible  A clinical event, including laboratory test abnormality, with a 
reasonable time sequence to drug administration, but which could 
also be explained by [CONTACT_9153]. 
Information on drug withdrawal may be lacking or unclear.  
Unlikely  A clinical event, including laboratory test abnormality, with a 
temporal relationship to drug administration which makes a causal 
relationship improbable, and which other drugs, chemicals or 
underlying disease provide plausible explanation.  
Unrelated  This category is applicable to AEs which are judged to be clearly and 
incontrovertibly due to extraneous causes (diseases, environment, 
etc.) and do not meet the criteria for drug relationship  listed for the 
above -mentioned conditions.  
 
All AEs will be evaluated by [CONTACT_978] /Sub-Investigator, who must approve the subject 
for subsequent dosing.  
Any AEs, whether serious or non -serious, will be monitored throughout the study 
and followed to resoluti on, when possible, regardless of whether the subject is still 
participating in the study.  
 
Adverse Event monitoring and reporting will be followed- up until resolution.  If 
resolution cannot be achieved within 1 week of study completion, the PI/Sub -
investigator will decide the course of action.  
11.2.2 Expectedness of SAE  
The Study PI [INVESTIGATOR_148246] . An adverse event will be considered unexpected if 
the nature, severity, or frequency of the event is not consistent with the risk 
information previously described in the Investig ator‚Äôs Brochure, Product 
Monograph, Product Label, or on the label of the drug.   
 BPS[LOCATION_003] Protocol Number : 2521  
Protocol Version Number:  3.0, Date: Jun 22, 2021 
Tacrolimus Capsule  
Fasting C onditions  
 
Page 45 of 68 
11.2.3 Severity Assessment  
The term "severe" describes the intensity (severity) of a specific event; the event 
itself, however, may be of relatively minor medical significance (such  as severe 
headache). This means it is not the same as "serious", which is based on 
patient/event outcome or action criteria usually associated with events that pose a 
threat to a patient's life or functioning  
The severity of all AEs will be graded by [CONTACT_978]/Sub -Investigator or a medical 
qualified delegate according to the following definitions:  
Every effort will be made to obtain an adequate evaluation of the severity.  
11.3 Adverse Events and Serious Adverse Event s Reporting  
An Adverse Event as defined above generally includes any condition that was:  
1) Not present prior to administration of study drugs but appeared after 
initiation of administration  of study drug; or 
2) Present prior to administration of study drugs but worsened after 
administration of study drug; or   
3) Reported as part of the subject's history, and while not present immediately 
prior to initiating administration of study drugs , reappeared after 
administration of study drug.  
 
During the study, an AE can also occur outside the time that the investigational 
product(s) was given (e .g., during a washout period).  
 
Pre-existing conditions, diseases, or disorders are not considered AEs  unless there 
is a change in intensity, frequency, or quality. Planned hospi[INVESTIGATOR_2144]/or 
surgical operations/procedures for an illness or disease that existed before the 
investigational product was given or the subject was enrolled in a clinical t rial are 
not to be considered AEs. 
 
Clinical laboratory data collected during the course of the study, which exceeds or 
drops below the acceptable limits for the subject population and which, based on 
baseline values, are considered by [CONTACT_16426], will 
be reported as an AE. If clinically significant abnormal ECGs and/or laboratory Mild  Adverse event resulting in discomfort, but not sufficient to cause 
interference in normal daily activities.  
Moderate  Adverse event resulting in discomfort that is sufficient to cause 
interference in daily activities.  
Severe  Adverse event resulting in discomfort causing an inability to carry out 
normal daily activities.  
 BPS[LOCATION_003] Protocol Number : 2521  
Protocol Version Number:  3.0, Date: Jun 22, 2021 
Tacrolimus Capsule  
Fasting C onditions  
 
Page 46 of 68 
values lead to, or are associated with clinical symptom(s), the diagnosis should be 
reported as an AE.  
If a subject discontinues  from the study because of  an AE, study site personnel must 
clearly document the circumstances and data leading to the reason for 
discontinuation. 
The investigator/designee is responsible for recording all AEs which have occurred 
during the study (including clinically important deviations of laboratory values from 
normal ranges), regardless of their relationship to the study drug s. This includes AEs 
spontaneously reported by [CONTACT_102], observed by [CONTACT_093]/designee or 
elicited by [CONTACT_148266]. All AEs will be determined as Serious or Non -
Serious .  
 
Subjects will be instructed to inform clinic personnel of AEs that may arise during 
the study.  
 
Treatment of any AEs will be administered under the direction of a physician, either 
at BPS [LOCATION_003]  or at a nearby [CONTACT_2360][INVESTIGATOR_9487]. First-aid treatment will be 
provided on site, but if additional treatment is required, subjects will be transferred 
to a hospi[INVESTIGATOR_307]. 
 
All symptoms will be recorded by [CONTACT_148267] /Sub-
Investigator prior to any subsequent dosing. When appropriate, medical tests and 
examinations will be performed to document resolution of the event(s).   
All reported adverse events will be documented in the Clinical Report.  
The Investigator will monitor the subject's conditi on until recovery to a satisfactory 
state or stabilization. Thus, follow -up visits may be required even after the 
administration of the study drugs has been discontinued.   
 
All SAE (s), whether or not the event is deemed study drug- related, will be reporte d 
to the Sponsor by [CONTACT_148268] [ADDRESS_169977] (IRB) or Independent Ethics Committee (IEC) and/or 
reported in accordance with local laws and regulations . 
Adverse events will be coded into the Preferred Term (PT), classified according to 
the Medical Dictionary for Regulatory Activities (MedDRA) with System Organ 
Classification (SOC) and reported with severity, duration, onset time and 
relationship to study drugs and action taken.  
BPS[LOCATION_003] will be responsible for notifying the local IRB. The Sponsor will be 
responsible for notifying the regulatory agencies, if applicable. BPS[LOCATION_003] will also 
report SAEs to FDA Adverse Event Reporting System (FAERS)  per their 
procedures. The Principal Investigator [INVESTIGATOR_148247] : 2521  
Protocol Version Number:  3.0, Date: Jun 22, 2021 
Tacrolimus Capsule  
Fasting C onditions  
 
Page 47 of 68 
Sponsor any unanticipated problems involving risk to human subjects or others 45 
CFR 46.103(b)(5)(i). Certain adverse events must be reported to the IRB within a specified period of time after the discovery of the event. The Office for Human Research Protections guidance defines these adverse events as including, but not limited to the following:  
‚àí An adverse event that is not expected, i.e., not listed in the informed consent 
document or the investigator‚Äôs brochure;  
‚àí An expected adverse event that occurs at a greater frequency or duration than 
expected;  
‚àí Any adverse event that would require modification of the protocol and/or 
informed consent document. 
All SAEs need to be emailed with SAE in a subject line to : 
 
 
  
 
  
 
11.[ADDRESS_169978] or any hCG level ‚â• 5 IU/L for females of child -
bearing potential and ‚â• 8 IU/L for post -menopausal females will be assessed as 
clinically significant and will result in the immediate dismissal of the subject from the study, unless deemed otherwise by [CONTACT_737]. The elevated hCG will be 
investigated as a potential pregnancy and will be followed up in the same manner as an AE . A confirmatory hCG blood test will be required for any elevated values. If 
pregnancy is confirmed, any out of range hCG levels will not be considered an adverse event . 
Once notified that pregnancy has occurred during the course of the study or within [ADDRESS_169979], to the PI/Sub-I nvestigator, the IRB, and 
appropriate Sponsor representative. A Pregnancy Notification Form will be completed as per BPS[LOCATION_003] internal Standard Operating Procedures and will be included alongside any pertinent information at the time of pregnancy reporting. The confirmed pregnancy will be followed to birth of the child or elective/spontaneous termination of the pregnancy. Follow up will occur at minimum once every three months ( i.e., once per trimester) until the end of the pregnancy (birth, termination, 
etc.).  
Elective termination will not be considered an adverse event, however supporting documentation detailing the outcome of the procedure will be required. Spontaneous 

 BPS[LOCATION_003] Protocol Number : 2521  
Protocol Version Number:  3.0, Date: Jun 22, 2021 
Tacrolimus Capsule  
Fasting C onditions  
 
Page 48 of 68 
termination of the pregnancy will be considered a Serious Adverse Event and will 
be foll owed up accordingly (as per S ection 11.3). Pregnancy will be treated as AEs 
for this study.  
 
12.[ADDRESS_169980] 1 study period will be analyzed for 
drug concentration.  
12.1.2 Analyte(s) in Biological Matrix  
Whole blood samples will be assayed for tacrolimus  using a validated analytical 
method according to the principles of Good Laboratory Practice.  
12.1.3 Incurred sample reproducibility  
Incurr ed Sample Reanalysis (ISR) shows repeatability and stability of an analytical 
method in real sample matrix.  Approximately 10% of the samples will be 
reanalyzed in case the number of samples is less than 1000 samples.  If the number 
of samples is greater t han 1000, 10% of the first 1000 samples and 5% of the 
remaining samples will be reanalyzed. The ISR test will contain samples from all 
analyzed subjects.   For each subject, at least two samples should be chosen, one at 
or near C max and the other one in the  elimination phase.  
 
If an ISR sample result is not valid for analytical reasons (e.g. low area of internal 
standard response, sample processing error, instrument failure etc.), this sample will 
be excluded from the statistical evaluation of the ISR test and will not be reanal yzed.  
Acceptance criterion of the ISR test: the concentration obtained for the initial 
analysis and the concentration obtained by [CONTACT_148269] 20% of their 
mean for at least 67% of the repeats.  If acceptance criterion of the ISR test is no t 
met, an investigation will be conducted to determine the reason for differences, and 
adequate steps will be taken to minimize inaccuracy (and imprecision).  
 
The ISR test results will be presented in the Bioanalytical Report; they will not be 
used for an y correction of the concentration results for pharmacokinetic and 
statistical evaluation of the study.  
 
 BPS[LOCATION_003] Protocol Number : 2521  
Protocol Version Number:  3.0, Date: Jun 22, [ADDRESS_169981] one of the  following subjects will be included in the PK and 
statistical analysis:  
1. Subjects who complete all study periods . 
2. Subjects who have missed samples but for whom it has been predicted prior 
to the start of bioanalytical analysis that reliable estimates of the PK 
parameters should be possible.  
3. Subjects who drop out from the study but have completed at least [ADDRESS_169982]‚Äôs pre -dose concentration is less than or equal to 5% of the C max value for 
that subject in the given period, then the subject‚Äôs data in that period without any 
adjustments can be included in all PK measurements and calculations. If the pre-
dose value is greater than 5% of the C max, data from that subject in that period  will 
be dropped from the PK and statistical analysis. Data for subjects dropped due to 
higher than 5% of C max pre-dose concentrations will be included in a separate 
appendix in the final study report.  
For subjects who are dismissed from the study due to non- compliance or any reason 
other than AEs ,  other data  of non- impacted period(s) for that subject, which fulfills 
the PK analysis data set requirement s, as above, will be included in PK stats analysis. 
Data does not fulfill the requirements will be presented separately.  
If a subject is dismissed/withdrawn due to an AE from a study period, the data from 
that period will not be included in the PK stats analysis and will be presented 
separately. All other data for that subject, which fulfills the PK analysis data set 
requirement, as above, will be included in PK stats analysis.  Data does not fulfill the 
requirements will be presented separately.  
Data from other subjects who were dismissed or withdrew due to  elevated hCG 
levels or are confirmed to be pregnant will not be included in the PK and statistical 
analysis.  The data for these subjects will be presented separately . 
 
Any decision for excluding data prior to start of sample bioanalysis (e.g Major 
protoco l deviation) will be provided with a detailed explanation and will be properly 
recorded and dated.  
13.2 Analysis of Pharmacokinetic Data  
The PK  and statistical analysis will be performed at BPSI using SAS¬Æ Version 9.4.  
The PK and/or statistical analyses outlin ed in this protocol may be altered with 
appropriate justification.  
 BPS[LOCATION_003] Protocol Number : 2521  
Protocol Version Number:  3.0, Date: Jun 22, 2021 
Tacrolimus Capsule  
Fasting C onditions  
 
Page 50 of 68 
13.2.1 Pharmacokinetic Analysis   
Pharmacokinetic parameters will be calculated using non -compartmental analysis 
(NCA) method. The following PK parameters will be estimated (where possible) for 
tacrolimus and included in the PK and statistical analysis:  
Primary endpoint  
AUC 72:  Area under the concentration -time curve from time zero 
until time point [ADDRESS_169983] dose . AUC 72 is estimated 
using the linear trapezoidal method.  
Cmax: The maximal observed whole blood concentration.  
 
Secondary endpoint  
AUC inf: Area under the concentration- time curve from time zero to 
infinity, calculated as AUC t + C last/Œª, where C last is the last 
measurable concentration.  
AUC t: Area under the concentration- time curve from time zero until the 
last measurable concentration or last sampling time t, whichever 
occurs first. AUC t is estimated using the linear trapezoidal 
method.  
T1/2: Terminal elimination half- life, estimated as ln(2)/Œª.  
Tmax: Time when the maximal whole blood concentration is observed. 
Œª: Terminal elimination rate constant, estimated by [CONTACT_148270] -concentration vs. time 
plot. 
 
During PK and statistical analyses, drug concentrations below the lower limit of 
quantitation (BLQ) of an assay will be cons idered as zero except when they occur 
between two non- BLQ concentrations where they will be considered as missing 
during PK  calculations and estimations.  
The actual time of blood samples collection will be used for pharmacokinetic and 
statistical analysis.  
Missed samples and non -reportable concentrations (e.g. quantity not sufficient) 
from the analytical laboratory will be treated in the pharmacokinetic analysis as if 
they have not been scheduled for collection.  
For subjects with missing or non- reportable tacrolimus concentration at time point 
72-hour or the sampling time deviation at 72 -hours is greater than 2 hours, the 
AUC 72 will not be calculated. If concentration(s) at 72 hours or at the time point(s) 
immediately preceding 72 hours is/ar e BLQ(s), this/these BLQ value(s) will be set 
as zero and the calculated AUC will be treated as AUC 72. 
 BPS[LOCATION_003] Protocol Number : 2521  
Protocol Version Number:  3.0, Date: Jun 22, 2021 
Tacrolimus Capsule  
Fasting C onditions  
 
Page 51 of 68 
The Œª, T 1/2, and AUC inf parameters will not be estimated for whole blood  
concentration -time profiles where the terminal linear phase is not clearly defin ed. 
For subjects with missing or non- reportable  tacrolimus  concentrations for three or 
more of the last samples, only the C max and T max will be presented and included in 
the statistical analysis. Other PK parameters will not be reported.  The AUC 72 could 
also be estimated for these subjects if data allows.  
13.2.2 Statistical Analysis  of Pharmacokinetic Data    
Step 1:  Determine the W ithin -subject S tandard D eviation  of the Test and 
Reference Products (  ùë∫ùë∫ùëæùëæùëæùëæ and  ùë∫ùë∫ùëæùëæùëæùëæ ) for the PK Parameters AUC 72, AUC t, 
AUC inf and C max:  
The within -subject standard deviation of the test and reference product s will be 
determined for the ln -transformed PK parameters AUC 72, AUC t, AUC inf and C max for 
tacrolimus .  
For a fully replicated [ADDRESS_169984],           can be determined as follows:  
 
Where,  
 Number of sequences (2 used in the study),  
Number of subjects within each sequence,  
  (where  represents the first administered (early) reference and 
 represents the second administered (late) reference.)  
 (Mean within sequence .) 
 (total number of subjects used in the study, while  is the number of 
subjects used in sequence .) 
 
 will be calculated as follows:  
 
 
The  calculation will include subjects with estimated PK parameters for both 
reference administrations.  )2(2) (2
12
1.
2
‚àí‚àí
=‚àë‚àë
==
nD D
Sin
ji ij
WRi
=i
=j
2 1 ij ij ij R R D‚àí=1ijR
2ijR
in
jij
inD
Di‚àë
==1
. i
‚àë
==2
1iin nin
i
WRS
2
WR WR S S=
WRS2
WRS
 BPS[LOCATION_003] Protocol Number : 2521  
Protocol Version Number:  3.0, Date: Jun 22, [ADDRESS_169985]  ùëÜùëÜùëäùëäùëäùëä as well . 
Step 2: Reference Scaled Average Bioequivalence Procedure 
The 95% upper confidence bound for  will be determined for the 
ln-transformed PK parameters AUC 72, AUC t, AUC inf and C max using a PROC 
MIXED model in SAS¬Æ, where   and are the means of the ln -transformed PK 
parameters obtained from the BE study for the test and reference products, 
respectively.  is the scaled average bioequivalence limit defined as ùúÉùúÉ=
ÔøΩln (10.9‚ÅÑ )
ùúéùúéùë§ùë§0ÔøΩ2
, where  is a regulatory constant which is set at 0.10. 
 
The method of obtaining the upper confidence bound is based on Howe‚Äôs 
Approximation [8]. The following steps will be followed to construct the 95% upper 
confidence bound. 
1. Let , ,  and be the log transformed observations on early test, 
late test, early reference and late reference for subject  within sequence i . 
Then we will calculate the following two terms:  
i. , and 
ii. . 
 
2. Fit the Generalized linear mixed  model (GLM M) with values as dependent 
variable.  Sequence is the explanatory variable of the model.  The confidence 
interval for the least squares mean of   will be estimated at 10% significance 
level. Let  and be the lower and upper bounds of the confidence interval. 
Also the least squares mean of  will be  calculated by [CONTACT_148271], using the ESTIMATE function of GLM M. Suppose 
 is the estimated least squares mean of  and  is the standard error of 
this estimate.  
 
Calculate the following estimates:  
 
 
3. Fit the GL MM with values as the dependent variable.  Sequence is the 
explanatory variable of the model.  The within subject variance of the reference 
product, , will be calculated as,  2 2) (WR R T SŒ∏¬µ¬µ ‚àí‚àí
T¬µR¬µ
Œ∏
0wœÉ
1ijT2ijT1ijR2ijR
j
2 22 1 2 1 ij ij ij ij
ijR R T TI+‚àí+=
2 1 ij ij ij R R D‚àí=
ijI
I
L U
I
2
Œ¶ I )(Œ¶SE
2 2
1 )(Œ¶‚àíŒ¶=‚àÜ SE
ijD
2
WRS2
1 (abs(U))))L)), (max((abs(=B
 BPS[LOCATION_003] Protocol Number : 2521  
Protocol Version Number:  3.0, Date: Jun 22, 2021 
Tacrolimus Capsule  
Fasting C onditions  
 
Page 53 of 68 
 
Where MSE is the mean square error from the model and let be the 
corresponding degrees of freedom.  
4. Now the 95% upper confidence bound for  will be calculated 
as follows:  
 
 
Where,  
 
 
 is the chi -square tabulated values at 5% significance level.  
 
Step 3: Unscaled Average Bioequivalence Procedure  
The unscaled average bioequivalence analysis was performed using PROC MIXED 
in SAS@, with SEQUENCE, PERIOD, and TREATMENT as fixed effects, 
TRE ATMENT and SUBJECT as random effects on the logarithm of the 
pharmacokinetic parameters (AUC 72, AUC t, AUC inf or C max).  
 
The following illustrates the program statements to run the ANOVA using PROC 
MIXED in SAS, with SEQ, SUBJ, PER, and TRT identifying sequence, subject, 
period, and treatment variables, respectively, and Y denoting the response measure 
(e.g.,ln( AUC 72), ln(AUC t), ln(  AUC inf), ln(Cmax)) being analyzed:  
PROC MIXED;  
 CLASSES SEQ SUBJ PER TRT;  
 MODEL Y = SEQ PERTRT / DDFM=SATTERTH;  
 RANDOM TRT/TYPE=FA0(2) SUB=SUBJ G;  
 REPEATED/GRP=TRT SUB=SUBJ;  
 ESTIMATE 'T vs. R' TRT 1 - 1/CL ALPHA=0.1;  
 
All the fixed effects will be tested using the Type [ADDRESS_169986] statistically significant differe nces (Œ±=0.05). 
The REPEATED statement in PROC MIXED is used to specify covariance 
structures for repeated measurements on subjects. Least squares means for the 
treatments and the adjusted difference between treatment means together with the 
associated stan dard error (œÉ D) will be estimated in this procedure.  22 MSESWR=
Œ∫
2 2) (WR R T SŒ∏¬µ¬µ ‚àí‚àí
2
2 22
1 1 2 1 ) () ( ) ( ‚àÜ‚àí+‚àÜ‚àí+‚àÜ+‚àÜ B B
2
2 WRSŒ∏‚àí=‚àÜ
2
95.0,2
2
Œ∫œáŒ∫‚àÜ=B
2
95.0,Œ∫œá
 BPS[LOCATION_003] Protocol Number : 2521  
Protocol Version Number:  3.0, Date: Jun 22, 2021 
Tacrolimus Capsule  
Fasting C onditions  
 
Page 54 of 68 
The two one -sided hypotheses  [9] at the alpha level (Œ±=0.05) of significance will be 
tested by [CONTACT_31362] 90% confidence interval for the ratio between the test and 
reference means.  
The same ANOVA using the linear mixed -effects model will be performed on the 
raw data for T max, Lamb da (or Œª), and T 1/2 parameters.  
 
Step 4: Calculate the 90% CI of the Ratio of the Within -subject Standard 
Deviation of T est Product to R eference Product  (ùùàùùàùëæùëæùëæùëæùùàùùàùëæùëæùëæùëæ‚ÅÑ ). 
 
The 90% CI for ùúéùúéùëäùëäùëäùëäùúéùúéùëäùëäùëäùëä‚ÅÑ  is given by 
 
ÔøΩùëÜùëÜùëäùëäùëäùëäùëÜùëÜùëäùëäùëäùëä‚ÅÑ
ùêπùêπùõºùõº2ÔøΩ(ùë£ùë£1,ùë£ùë£2),ùëÜùëÜùëäùëäùëäùëäùëÜùëÜùëäùëäùëäùëä‚ÅÑ
ùêπùêπ1‚àíùõºùõº2ÔøΩ(ùë£ùë£1,ùë£ùë£2) ÔøΩ 
where  
‚Ä¢ ùëÜùëÜùëäùëäùëäùëä is the estimate of ùúéùúéùëäùëäùëäùëä with ùë£ùë£1 as the degree of freedom;  
‚Ä¢ ùëÜùëÜùëäùëäùëäùëä is the estimate of ùúéùúéùëäùëäùëäùëä with ùë£ùë£2 as the degree of freedom;  
‚Ä¢ ùêπùêπùõºùõº2ÔøΩ(ùë£ùë£1,ùë£ùë£2) is the value of the F -distribution with ùë£ùë£1(numerator) and 
ùë£ùë£2 (denominator) degrees of freedom that has the probability of ùõºùõº2ÔøΩ to its right  
‚Ä¢ ùêπùêπ1‚àíùõºùõº2ÔøΩ(ùë£ùë£1,ùë£ùë£2) is the value of the F -distribution with ùë£ùë£1(numerator) and 
ùë£ùë£2 (denominator) degrees of freedom that has the probability of 1‚àíùõºùõº2ÔøΩ to its 
right  
‚Ä¢ here ùõºùõº=0.1. 
 
Individual concentration at each scheduled time point and individual PK parameters 
will be listed  by [CONTACT_3148] . Two SAS transport files including xconc.xpt for 
individual concentration at each scheduled time point and xpara.xpt for individual 
PK parameters, as well as a Define.pdf file  to descri be each SAS transport file  will 
be provided.  
 
Descriptive statistics ( including number of subjects (N), arithmetic mean, standard 
deviation (SD), minimum, maximum, median and coefficient of variation (CV%)) 
of concentrati ons will be presented by [CONTACT_94311].  
 
Descriptive statistics (including N, arithmetic mean, SD, minimum, maximum, 
median and CV%)  of all PK  parameters will be presented  by [CONTACT_3148] . 
 
The mean and individual concentration- time profiles will be plotted in linear and 
semi -logarithmic scales.  
 
If the study is dosed in two or more groups of subjects, the statistical model will be 
modified to reflect the multi -group nature of the study.  
Additional statis tical and alternate tests will be performed if necessary.  
 BPS[LOCATION_003] Protocol Number : 2521  
Protocol Version Number:  3.0, Date: Jun 22, 2021 
Tacrolimus Capsule  
Fasting C onditions  
 
Page 55 of 68 
 
Further details for statistical analysis of PK data will be described in the  Statistical 
Analysis Plan  (SAP).  
13.3 Safety Analysis  
13.3.1 Safety Data Set  
Safety data set is defined as all subjects dosed in thi s study. In a case where SARS -
CoV- 2 related TEAEs lead to the withdrawal  or dismissal of approximately 5 % or  
more of the dosed subjects, a subgroup analysis related to Adverse Events (AE) may 
be performed. And the safety listings and tables for AE with subgroup and the  total 
safety population will both be presented.  
 
13.3.2 Safety Listings  
The safety analysis data set  for Adverse Events (AE), demographic characteristics, 
vital signs  and clinical laboratory will be listed by [CONTACT_148272].  
 
A complete listing of AE or (Serious Adverse Events) SAE (if applicable) including 
period, actual treatment received, primary System Organ Class (SOC) and Preferred 
Term (PT), reported term, AE severity, AE causality , start/end date and time, 
duration, action taken etc., will be presented by [CONTACT_1130].  
 
A comp lete listing of demographic characteristics including age, race, gender, 
ethnicity, BMI, weight and height will be presented by [CONTACT_1130].  
 
Vital signs parameters including Systolic Blood Pressure (SBP), Diastolic Blood 
Pressure (DBP), Heart R ate (HR), Respi [INVESTIGATOR_13581] (RR), temperature and oxygen 
saturation (if applicable) will be presented by [CONTACT_1130].  
 
A complete listing of clinical laboratory measurements ( including hematology, 
serum chemistry, urinalysis, serology, breath alcohol test, urine tests for drugs of 
abuse, urine HCG test (for females),  serum HCG test (for females), magnesium, 
creatinine kinase and lipid panel  will be presented by [CONTACT_1130].  
13.3.3 Safety Tables  
The safety data set  for AE, demographic characteristics and vital signs will be 
summarized in frequency or using descriptive statistics ( including N, arithmetic 
mean, SD, minimum, maximum and median ) of quantitative  measures by [CONTACT_3148], 
as appropriate.  
 
 BPS[LOCATION_003] Protocol Number : 2521  
Protocol Version Number:  3.0, Date: Jun 22, 2021 
Tacrolimus Capsule  
Fasting C onditions  
 
Page 56 of 68 
A brief overall summary of AEs including number of AEs/TEAEs  (Treatment 
Emergent Adverse Even t) /SAEs and number and percentage of subjects experienced 
at least one AEs/TEAEs/SAEs will be presented by [CONTACT_148273]. TEAEs/SAEs will also be summarized using the number and percentage 
of subjects experiencing at least one TEAE/ SAE (with the number of subjects who 
received study treatment as the denominator of percentage) by [CONTACT_148274], PT, AE 
severity and AE causality, for each treatment and the overall population.  
 
Descriptive statistics of age, BMI, weight and height and fre quencies for race, gender 
and ethnicity will be provided by [CONTACT_148275].  
 
Descriptive statistics of each vital sign ‚Äôs parameter s will be presented by [CONTACT_148276].  
 
Descriptive statistics of all quantitative measurements from all clinical laboratory 
parameters will be presented by [CONTACT_11876], laboratory parameter, 
and visit.  
 
Further details for safety analysis will be described in the  Statistical Analysis Plan  
(SAP).  
13.4 Bioequivalence Criteria  [7, 10]  
To establish bioequivalence, all the following conditions for individual PK 
parameter(s) AUC 72, and C max must be met:  
‚Ä¢ The 90% CI for the Test/Reference ratios of geometric means are completely 
contained within 80.00% -125.00% .  
‚Ä¢ The 95% upper confidence bound for  should be less than 
or equal to 0 . 
‚Ä¢ The upper limit of the 90% confidence interval for the Test/ Reference ratio of 
the within -subject standard deviation  (ùùàùùàùëæùëæùëæùëæùùàùùàùëæùëæùëæùëæ‚ÅÑ ) is less than or equal to 2.5. 
 2 2) (WR R T SŒ∏¬µ¬µ ‚àí‚àí
 BPS[LOCATION_003] Protocol Number : 2521  
Protocol Version Number:  3.0, Date: Jun 22, 2021 
Tacrolimus Capsule  
Fasting C onditions  
 
Page 57 of 68 
14.0 ETHICAL CONSIDERATIONS  / PROTECTION OF HUMAN SUBJECTS  
14.1 Basic Principles  
This research will be carried out in accordance with Good Clinical Practice (GCP) 
as set out by [CONTACT_8639] (ICH) , the basic 
principles defined in the U.S. Code of Federal Regulations (21 CFR Part 312), the 
Belmont Report, Directive 2001/ 20/EC (Europe), and the principles enunciated in 
the most recent version of the World Medical Association Declaration of Helsinki.  
14.[ADDRESS_169987] (IRB) for this study. This 
Protocol and the ICF will be reviewed and approved by [CONTACT_148277]. Termination / suspension of any prior approval / favora ble opi[INVESTIGATOR_148248]  (Institutional Ethics Committee)/IRB . 
The board is constituted and operates in accordance with Division 5 of the Food and 
Drug Regulations, ICH Harmonized Tripartite Guideline (GCP Consolidated 
Guideline), and [ADDRESS_169988] parties (except to the IRB, FDA and/or relevant regulatory agencies). These 
restrictions will apply as well to all future communications if deemed privileged or 
confidential.  
Sponsor, study monitors, auditors, the IRB, FDA  and applicable regulatory 
authorities will be granted direct access to the subject‚Äôs original medical records for 
verification of clinical trial procedure and/or data, without violating the 
confidentiality of the subject, to the extent permitted by [CONTACT_148278], by [CONTACT_2960] a written informed consent form , the subject or the 
subjects legally  acceptable representative is authorizing such access.  
All documentation collected by [CONTACT_148279]/BPS[LOCATION_003]  Inc. will be kept confidential. The 
name [CONTACT_148284]. If documents containing 
 BPS[LOCATION_003] Protocol Number : 2521  
Protocol Version Number:  3.0, Date: Jun 22, 2021 
Tacrolimus Capsule  
Fasting C onditions  
 
Page 58 of 68 
the subjects‚Äô names are photocopi[INVESTIGATOR_530], the name [CONTACT_148285][INVESTIGATOR_148249]. 
The Certificate of Confidentiality  (CoC) , issued by [CONTACT_148280] 21st Century Cures Act, will be filed and maintained in the 
regulatory binder. As per the CoC, r esearchers cannot disclose a subject‚Äôs name [CONTACT_148286], criminal, administrative, 
legislative or other proceedings (such as a court trial), without their consent. Also, 
information collected for this research that could identify a subject  cannot be used 
as evidence in a legal proceeding without t heir consent.  
In addition, with the CoC , researchers involved in this study generally may not 
provide a subject‚Äôs name, or any other information that could identify them , to 
anyone who is not connected with the research. However, in the following situations, the C oC does not prevent the researchers involved in this study from disclosing 
study information that could identify a subject : 
‚Ä¢ If the subject  consents to someone receiving their  information from this study, 
including situations where the information is necessary for their medical 
treatment  
‚Ä¢ When the subject‚Äôs study information is used for other scientific research, as 
allowed by [CONTACT_92452]  
‚Ä¢ When information is needed by [CONTACT_1622], which is funding this study, in order  
to audit or evaluate federally-funded studies 
‚Ä¢ When a law  otherwise requires disclosure [ such as requirements to 1) make 
certain reports to FDA, 2) report threats of harm to self/others , 3) report 
incidents of child abuse, or 4) report cases of contagious disease, such as HIV, to the state as mandated by [CONTACT_76522] ]. This does not apply to disclosure in a 
legal proceeding.  
The C oC does not prevent a subject  from voluntarily providing information about 
themselves or their involvement in this research study t o others.  
The CoC will not be used to prevent disclosure for any purpose the subject  has 
consented to in this ICF, such as sharing their participation and research data with 
their family doctor (if the subject  has agreed to share this information).  
14.5 Compensation for Participation  
 
 
 
 
 
 
 
: 

 BPS[LOCATION_003] Protocol Number : 2521  
Protocol Version Number:  3.0, Date: Jun 22, 2021 
Tacrolimus Capsule  
Fasting C onditions  
 
Page 59 of 68 
 
  
  
  
  
  
  
  
  
  
 
 
 
 

 BPS[LOCATION_003] Protocol Number : 2521  
Protocol Version Number:  3.0, Date: Jun 22, 2021 
Tacrolimus Capsule  
Fasting C onditions  
 
Page 60 of 68 
 
 
 
 
 
 
 
  
 
 
 
 
 
  
 
15.0 ADMINISTRATIVE CONSIDERATIONS  
15.1 Revisions and/or Amendments to the Protocol 
Revisions and/or amendments to the protocol must be documented and approved by 
[CONTACT_079] [INVESTIGATOR_148250] . If the 
revision/amendment will affect subject safety and/or study design, the amendment will be re -submitted to the IRB for approval. Administrative changes ( i.e., change 
of analytical facility, typographical errors, discrepancies, clarifications) will also be submitted to the IRB, but may not require approval. A copy of the IRB‚Äôs approval 
or acknowledgement documents will be included in the final report. 
 For revisions or amendments to the protocol that substantially alter the study design after initiation of the study, a signed revised informed consent form  will be needed 
for continued participation by [CONTACT_423]. 
15.2 Investigator Responsibilities  
The Principal Investigator [INVESTIGATOR_148251], the current revision of the Declaration of Helsinki, ICH - GCP guidelines and applicable regulatory requirements. 
15.3 Study Completion/Termination 
BioPharma Services [LOCATION_003] Inc. and/or the Sponsor reserve t he right to terminate the 
study at any time for any reason related to the safety of subjects or due to any other non-study specific reason . 

 BPS[LOCATION_003] Protocol Number : 2521  
Protocol Version Number:  3.0, Date: Jun 22, 2021 
Tacrolimus Capsule  
Fasting C onditions  
 
Page 61 of 68 
15.4 Sponsor Visits  
The Sponsor is encouraged to visit BioPharma Services [LOCATION_003] Inc., if desired, and at 
their convenience.  The PI [INVESTIGATOR_148252], if requested, all source documents 
and/or other study- related documents. The PI  [INVESTIGATOR_148253].  
 
16.0 DATA MANAGEMENT/RECORD KEEPI[INVESTIGATOR_1645]  
16.1 Source Data  
All data will be recorded in accordance with GCP to ensure accuracy, completeness, 
legibility, and timeliness of the data reported.  
 
All data will be recorded directly on the source documents and  will be considered 
source data . Subjects will be identified using an assigned ID number and/or 
randomization number on source documents.  
16.2 Quality of Data  
All source documents and laboratory reports will be Quality Control reviewed to 
ensure accuracy and completeness. Adverse events will be reviewed and assessed 
for severity and causality by [CONTACT_978] /Sub-Investigator . Specific processes of the study, 
its source documentation and any report s (if applicable) will be audited by [CONTACT_148281]  (QA)  unit of BPSI /BPS[LOCATION_003] . 
16.[ADDRESS_169989] 25 years from the completion of the study and will be 
available for inspection by [CONTACT_1052]/or Regulatory Agencies .  
 BPS[LOCATION_003] Protocol Number : 2521  
Protocol Version Number:  3.0, Date: Jun 22, 2021 
Tacrolimus Capsule  
Fasting C onditions  
 
Page 62 of 68 
17.0  REFERENCES  
1. Zhang W et al. , Recent Topi[INVESTIGATOR_148254]- Related , Int J Mol Sci. 2019, 20(13):3210.  
2. Gaynor J et al.,  Lower tacrolimus trough levels are associated with 
subsequently higher acute rejection risk during the first 12 months after kidney 
transplantation . Transplant International, 2016, 29: 216  
3. Sikma  M et al.,  Association of Whole Blood Tacrolimus Concentrations with 
Kidney Injury in Heart Transplantation Patients, Eur J Drug Metab 
Pharmacokinet. 2018; 43(3): 311. 
4. Hitesh S. Purohit et al., Investigating the Impact of Drug Crystallinity in Amorphous Tacrolimus Capsules on Pharmacokinetics and Bioequivalence Using Discriminatory In Vitro Disso lution Testing and Physiologically Based 
Pharmacokinetic Modeling and Simulation, J Pharm Sci. 2018, 107(5):[ADDRESS_169990] of Endogenously Derived 
Crystalline Drug on the in Vivo Performance of Amorphous Formulations . Mol. 
Pharmaceutics 2019, 16 (8): 3617  
6. PROGRAF
¬Æ (tacrolimus) capsules, for oral use, [label ].  
 
7. FDA draft guidance on Tacrolimus capsule (revised on Dec 2012) 
https://www.accessdata.fda.gov/drugsatfda_docs/psg/Tacrolimus_cap_50708_
RV12 -12.pdf  
8. W. G. Howe (1974), Approximate Confidence Limits on the Mean of X+Y Where X and Y are Two Tabled Independent Random Variables,  Journal of 
the American Statistical Association , 69 (347): 789 ‚Äì 794. 
9. Schuirmann DJ.  A comparison of the two one- sided tests procedure and the 
power approach for assessing the equivalence of average bioavailability.  J. Pharmacokinet BioPharm 1987; 15:657-80. 
10. FDA draft guidance on Warfarin Sodium tablet (revised on Dec 2012) 
https://www.accessdata.fda.gov/drugsatfda_docs/psg/Warfarin_Sodium_tab_0
9218_R C12-12.pdf  
 

 BPS[LOCATION_003] Protocol Number : 2521  
Protocol Version Number:  3.0, Date: Jun 22, 2021 
Tacrolimus Capsule  
Fasting C onditions  
 
Page 63 of 68 
APPENDIX A  ‚Äì SCHEDULE OF EVENTS  
 Screening  Check
-in Period 1, 2, [ADDRESS_169991] visit of 
Period 4  
Confinement   X X X X X#     
ICF X          
Demographics  X          
Medical/Medication History  X          
Physical Exam  X         X 
Body weight  X          
Height  X          
BMI  X          
Vital Signs (BP & HR)  X X Xa Xb Xc Xd    X 
Safety measures for 
COVID -19# (Symptom 
Check, Temperature, Pulse 
Oximetry and RR)   
X  
 
Xe  
Xe  
  Xe  
 
Xe  
 
Xe 
  
 
X  
 
X  
 
X  
SARS -CoV -[ADDRESS_169992]  (If 
applicable)   X         
Urine Drug Tests  X X         
Alcohol Test  X X         
Pregnancy Test  X* X*         
12-Lead ECG  X          
Hematology  X X        X 
Serum Chemistry  X Xf        X 
Urinalysis  X X        X 
Serology  
(HIV, Hepatitis B and C)  
Magnesium  
Creatinine Kinase  
Lipid panel  X  
        
Inclusion/Exclusion criteria  X Xg         
Compliance check   X     X X X  
Randomization    X        
Tacrolimus Capsule 
Administration    X        
PK Sampling    Xh Xh Xh Xh Xh Xh Xh  
Questioning subjects if use of 
any c oncomitant medication  X X     X X X  
Adverse Events    X X X X X X X  
Meals   X X X X X     
* Serum pregnancy test at screening and urine pregnancy test at each period check-in.  
# Study exit at [ADDRESS_169993] -dose tacrolimus  
a: 1, 2, [ADDRESS_169994]-dose  
b: 24hours post -dose 
c: [ADDRESS_169995] -dose 
d: [ADDRESS_169996] -dose 
e: At pre -dose, at 6- and 12-hours  post-dose  and then at every 12 hours  until discharge  at each study period . 
f: At check -in period 1 and 3 . 
 BPS[LOCATION_003] Protocol Number : 2521  
Protocol Version Number:  3.0, Date: Jun 22, 2021 
Tacrolimus Capsule  
Fasting C onditions  
 
Page 64 of 68 
g: Only at check -in for the period 1  
h: Pre-dose (0 hour) and at 0.25, 0.50, 0.75, 1.00, 1.25, 1.50, 1.75, 2.00, 2.25, 2.50, 2.75, 3.00, 3.50, 4.00, 5.00, 6.00, 8.00, 10.00, 
12.00, 16.000, 24.000, 36.00, 48.00, 72.00, 96.00, 120.00 and 144.00 hours after study drug dosing in each study period 
 BPS[LOCATION_003] Protocol Number : 2521  
Protocol Version Number:  3.0, Date: Jun 22, 2021 
Tacrolimus Capsule  
Fasting C onditions  
 
Page 65 of 68 
APPENDIX B  ‚Äì CLINICAL LABORATORY ASSESSMENT  
TYPE OF 
TEST  COMPONENTS  
Hematology4 ‚Ä¢ Hemoglobin  
‚Ä¢ Hematocrit  ‚Ä¢ RBC  
‚Ä¢ Platelet count  ‚Ä¢ WBC and automated differential   
Serum5 
Chemistry  ‚Ä¢ Glucose  
‚Ä¢ Calcium  
‚Ä¢ Sodium  
‚Ä¢ Chloride  
‚Ä¢ Bicarbonate 
(Total CO 2)  
‚Ä¢ Albumin  
‚Ä¢ Protein  
‚Ä¢ Bilirubin  
 
 ‚Ä¢ AST  
‚Ä¢ ALT  
‚Ä¢ Potassium  
‚Ä¢ Alkaline 
Phosphatase  ‚Ä¢ BUN  
‚Ä¢ Urea  
‚Ä¢ Uric Acid  
‚Ä¢ Creatinine  
Urinalysis  ‚Ä¢ Bilirubin  
‚Ä¢ Blood  
‚Ä¢ Glucose  ‚Ä¢ pH  
‚Ä¢ Ketones  
‚Ä¢ Leukocytes  ‚Ä¢ Nitrites  
‚Ä¢ Protein  ‚Ä¢ Specific Gravity  
Additional 
Tests  Serology (HIV, Hepatitis B surface 
antigen, Hepatitis C antibody)[ADDRESS_169997] 
Serum hCG (only females, at Screening)  
Urine hCG (only females, at each period 
check -in) 
Urine Tests 
for Drugs of 
Abuse  Marijuana, Amphetamines, Phencyclidine, Barbiturates, Cocaine, Opi[INVESTIGATOR_858], 
Benzodiazepi[INVESTIGATOR_1651]  
 
 
 
  
 
4 At Screening, at each check -in and at EOS  
5 At screening, at check -in for period 1 and 3 and at EOS  
6 At screening only  
 BPS[LOCATION_003] Protocol Number : 2521  
Protocol Version Number:  3.0, Date: Jun 22, 2021 
Tacrolimus Capsule  
Fasting C onditions  
 
Page 66 of 68 
APPENDIX C  ‚Äì LIST OF COMMON ABBREVIATIONS  
AE: Adverse Event  LSMEANS:  Least Square Means  
ALT:  Alanine Aminotransferase  MedDRA:  Medical Dictionary for Regulatory Activities  
ANOVA  Analysis of Variance  mg: Milligram  
AST:  Aspartate Aminotransferase  mL: Milliliters  
AUC [ADDRESS_169998] dose. AUC 72 is estimated using the 
linear trapezoidal method . mmHg:  Millimeter of Mercury  
AUC t: Area under the concentration -time curve 
from time zero until the last measurable 
concentration or last sampling time t, 
whichever occurs first. AUC t is 
estimated using the trapezoidal method  N/A or NA:  Not applicable, Not Available  
AUC inf: Area under the concentration -time curve 
from time zero to infinity, calculated as 
AUC t + C last/Œª, where C last is the last 
measurable concentration  PI: [INVESTIGATOR_148255] œÑ,ss: Area under the concentration -time curve 
from time  0 to œÑ (the length of the dosing 
interval) at steady state. AUC œÑ is 
estimated using the trapezoidal method.  PK: Pharmacokinetic  
BLQ  Below the Limit of Quantitation / Below 
Quantitation Limit  PT: Preferred Term  
BMI:  Body Mass Index (kg/m2) QA: Quality Assurance  
BP: Blood Pressure  RBC:  Red Blood Cell  
BPM:  Beats Per Minute  RPM:  Revolutions Per Minute  
BPSI:  BioPharma Services Inc.  RR: Respi[INVESTIGATOR_148256]:  BioPharma Services [LOCATION_003] Inc. RLD:  Reference Listed Drug  
cGMP  Current Good Manufacturing Practice  SAE:  Serious Adverse Event  
CI: Confidence Interval  SAS¬Æ: Statistical Analysis System  
Cmax: The maximal observed -whole blood 
concentration.  SD or STD:  Standard Deviation 
CoC Certificate of Confidentiality  SOC:  System Organ Classification  
CYP:  Cytochrome P450  SOP:  Standard Operating Procedure  
ECG:  Electrocardiogram  Sub-I Sub-Investigator  
FDA:  Food and Drug Administration  T1/2: Terminal elimination half -life, estimated as 
ln(2)/Œª  
FSH:  Follicle -Stimulating Hormone  Tmax / tmax: Time when the maximal -whole blood 
concentration is observed  
GCP:  Good Clinical Practice  WBC:  White Blood Cell  
GLP:  Good Laboratory Practice    
hCG:  Human Chorionic Gonadotropin    
HIV:  Human Immunodeficiency Virus    
ICF: Informed Consent Form    
ICH:  International Conference on 
Harmonization    
IEC Institutional Ethic Committee    
IRB:  Institutional Review Board    
 BPS[LOCATION_003] Protocol Number : 2521  
Protocol Version Number:  3.0, Date: Jun 22, 2021 
Tacrolimus Capsule  
Fasting C onditions  
 
Page 67 of 68 
Lambda / Œª:  Terminal elimination rate constant, 
estimated by [CONTACT_148282]-
concentration vs. time plot    
kg/m2: Kilogram/Meter Squared    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 BPS[LOCATION_003] Protocol Number : 2521  
Protocol Version Number:  3.0, Date: Jun 22, 2021 
Tacrolimus Capsule  
Fasting C onditions  
 
Page 68 of 68 
APPENDIX D ‚Äì P ROGRAF¬Æ LABEL  
(See attached)  
 